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Abstract 
 
Growth rate of prostate cancer tumor is an important aspect of understanding the natural 
history of prostate cancer. Using real prostate cancer data from the SEER database with 
tumor size as a response variable, we have clustered the cancerous tumor sizes into age 
groups to enhance its analytical behavior. The rate of change of the response variable as a 
function of age is given for each cluster. Residual analysis attests to the quality of the 
analytical model and the subject estimates. In addition, we have identified the probability 
distribution that characterize the behavior of the response variable and proceeded with 
basic parametric analysis. 
There are several remarkable treatment options available for prostate cancer patients. In 
this present study, we have considered the three commonly used treatment for prostate 
cancer: radiation therapy, surgery, and combination of surgery and radiation therapy. The 
study uses data from the SEER database to evaluate and rank the effectiveness of these 
treatment options using survival analysis in conjunction with basic parametric analysis. 
The evaluation is based on the stage of the prostate cancer classification. 
Improvement in prostate cancer disease can be measured by improvement in its mortality. 
Also, mortality projection is crucial for policy makers and the financial stability of 
insurance business. Our research applies a parametric model proposed by Renshaw et al. 
(1996) to project the force of mortality for prostate cancer. The proposed modeling 
structure can pick up both age and year effects. 
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Chapter 1: Introduction 
 
1.1 Background of Prostate Cancer 
A normal body has several living cells which grow, divide, and die. The cells divide 
faster to allow human growth at the early years. During adulthood, they divide mostly to 
replace dying or worn-out cells. 
Cancer generally begins when cells start to grow out of control at a particular part of the 
body. This abnormal or out of control growth of cells are characteristic of all kinds of 
cancer. Most cancer cells form a tumor which can spread to other tissues or parts of the 
body forming new tumors that replace normal cells. This process is called metastasis. 
Metastasis usually occurs when cancer cells get into the bloodstream or lymph vessels of 
the body. Note that, not all tumors are cancerous. However, a study by Chan (2012) 
showed that there is a reasonable exponential relationship between the size of a prostate 
tumor and the likelihood that the tumor would be cancerous. A cancerous tumor is 
referred to as malignant and a non-cancerous tumor is referred to as benign. Benign 
tumors usually grow and press on other healthy organs and tissues but do not invade the 
organs or tissues neither does it metastasize making it less life threatening. 
Prostate cancer can be understood by describing the prostate and other organs around it. 
See Figure 1.1 for a picture of the prostate. The prostate, found in only men, is a walnut-
size gland below the urinary bladder and in front of the rectum in the male reproductive 
system. The role of the prostate is to produce fluid that protects and nourishes sperm cells 
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in semen. Behind the prostate is the seminal vesicle which produces most of the fluid for 
semen. A tube called urethra, which goes through the center of the prostate, carries urine 
and semen out of the body through the penis. The prostate has several types of cells but 
almost all prostate cancers are formed in tissues of the prostate gland. The most common 
cancer that starts in the gland cells is called adenocarcinoma. 
 
Figure 1.1: Picture of the prostate 
Historically, Surgeon J. Adams at the London Hospital described the first case of prostate 
cancer in 1853, and for over a hundred and fifty years, prostate cancer has become a 
significant health issue around the globe and especially in the United States because it is 
the most common cancer in American men and also the second leading cause of cancer 
death in American men behind lung cancer. In 2012, it was estimated that about 241,740 
new cases of prostate cancer will be diagnosed and 28,170 will die of prostate cancer 
representing approximately 11.7% of the estimated deaths by prostate cancer diagnosis 
[American Cancer Society]. This year, the estimated new cases of prostate cancer in the 
U.S. are approximately 238,590 with an estimated 29,720 deaths representing about 
12.5% of the estimated deaths by prostate cancer [SEER and National Cancer Institute]. 
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Prostate cancer usually occurs in older men but it is very predominant among men at age 
67 years [Chan, Bonsu, & Tsokos, 2012]. About one in every six men will be diagnosed 
with prostate cancer during his lifetime and one in every thirty-six will die of prostate 
cancer [American Cancer Society]. Early detection of prostate cancer can be achieved 
through screening. Screening in this context refers to testing men with no symptoms of 
prostate cancer for any possible trace of the disease. The most commonly used prostate 
cancer screening methods are the prostate-specific antigen (PSA) test and the digital 
rectal exam (DRE).  
The PSA test measures the amount of prostate-specific in the blood. Medically, most 
healthy men have PSA level under 4 nanograms per milliliter (ng/ml) of blood. However 
levels below 4 ng/ml does not necessary guarantee the absence of prostate cancer. The 
most widely used type of PSA test is the percent-free prostate-specific antigen (fPSA) 
which requires two separate tests (i.e. the total and free PSA). The fPSA is the ratio of 
how much free PSA circulates in the blood compared to the total PSA level. A lower 
fPSA (10% or less) indicates a higher chance of having prostate cancer. However, it is 
important to point out that not all physicians use the same PSA cutoff point.  
Digital rectal exam is a procedure whereby a doctor inserts a finger into the rectum of a 
man to feel any bumps on the prostate gland as possible indication of a cancer. This 
method of screening is very uncomfortable and less effective than the PSA blood test. 
The DRE and/or the PSA test may fail to accurately detect prostate cancer in men. 
However, if there are discrepancies in the results of the screening test or the test suggests 
a high chance of having prostate cancer, then prostate biopsy is recommended to 
accurately diagnose the existence of cancer cells. 
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In general, a biopsy is a procedure where samples of body tissue are removed and viewed 
by a pathologist (a doctor who specializes in diagnosing disease in tissue samples) under 
a microscope. The main biopsy method for prostate cancer diagnosis is a core needle 
biopsy. This procedure requires the insertion of thin hollow needle through the wall of 
the rectum into the prostate gland and the needle pulled out to remove samples of the 
prostate tissue. The samples are viewed by the pathologist to determine the existence of 
cancer cells. Even with a biopsy, cancer can be missed partly because the biopsy needle 
may not pass through the cancer cell. Thus, to aid a biopsy, a standard ultrasound has 
been introduced as an integral part of the procedure. In an event where a biopsy fails to 
accurately detect a cancer but strong evidence exist through screening; a repeat of the 
biopsy may be required. When cancer cells are identified, the pathologist assigns a grade 
according to the Gleason system. 
One major factor in choosing prostate cancer treatment option is the extent (stage) of the 
cancer. The stage of a cancer is basically a standard measure to describe how far a cancer 
has spread. There are two types, namely, the clinical stage and the pathologic stage. The 
clinical stage involves the use of results of physical exam including DRE, lab test, 
prostate biopsy and any imaging test, whereas, the pathologic stage is solely based on 
surgery and examination of the removed tissue. The most widely used prostate cancer 
staging system is the American Joint Committee on Cancer (AJCC) system. 
After being diagnosed with prostate cancer, graded and staged, there are several treatment 
options available but not limited to surgery, radiation therapy, chemotherapy, hormone 
therapy, cryosurgery (cryotherapy), vaccine treatment, and expectant management 
(watchful waiting/active surveillance). Generally, these treatments are used one at a time 
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but sometimes they may be combined. For example, combination of surgery and radiation 
therapy is one form of a combine treatment option. Opinions regarding the best treatment 
option for a prostate cancer patient may differ among doctors. Therefore, it is necessary 
to consider some basic factors such as the grade and stage of the cancer, age of the 
patient, and any other potential health condition/s together with the benefits, side effects 
and risks of each treatment option. 
Currently, active research is going on throughout the world to help improve screening, 
diagnosis, and treatment of prostate cancer. In regards to screening, researchers are 
looking into other possible methods that may be more effective than the fPSA and DRE. 
Some of the new developed screening methods yet to be made available to physicians are 
the complexed PSA (measures the portion of PSA that is not free), urine test, and several 
newer tests based on other tumor makers. Prostate biopsy mostly relies on ultrasound but 
sometimes the standard ultrasound fail to detect some areas containing cancer. A newer 
technique called color Doppler ultrasound is underway. This approach measures blood 
flow within the gland since most tumors often have more blood vessels around them than 
the normal tissues. This increases the accuracy level of the prostate biopsy since the 
appropriate part of the gland will be identified to be sampled. More studies are already 
ongoing to enhance the color Doppler further. Also, researchers are looking into the use 
of magnetic resonance imaging (MRI) to guide prostate biopsy. Active research is also 
ongoing to develop newer treatments and improve existing standard treatment methods. 
Innovations in genetics has resulted in a study on genes that are linked to prostate cancer 
to help scientist and medical practitioners better understand how prostate cancer develops 
so that appropriate medicines may be designed to target changes in the gene/s. 
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1.2 An Overview of the SEER Program and Database 
The Surveillance, Epidemiology, and End Results (SEER) program of the National 
Cancer Institute (NCI) began on January 1, 1973. It is the premier source of information 
for various types of cancers and cancer statistics in the United States. SEER routinely 
collects data on cancer incidence and survival from specific locations and sources 
throughout the United States representing approximately twenty-eight percent of the U.S. 
population. It also collects data on patient demographics, primary tumor site, tumor 
morphology and stage at diagnosis, first course of treatment, and follow-up for vital 
status. The SEER program also compiles and publishes reports on cancer incidence and 
survival plus cancer mortality for the entire country. The mortality data are provided by 
the National Center for Health Statistics with the population based information obtained 
periodically from the U.S. Census Bureau and updated annually. 
The SEER data collection began with nine registries in the states of Connecticut, Iowa, 
New Mexico, Utah, and Hawaii and the metropolitan areas of Detroit and San Francisco-
Oakland in 1973. The 13-county Seattle-Puget Sound and the metropolitan area of 
Atlanta were later added in 1974 and 1975, respectively. Today, the data collection has 
increased to eighteen registries and continues to expand to include even more geographic 
areas and demographics. The added registries are; Louisiana (1974-1977, rejoined 2001), 
Rural Georgia (1978), New Jersey (1979-1989, rejoined 2001), Alaska Native Tumor 
Registry (1992), Los Angeles County (1992), San Jose-Monterey (1992), Greater 
California (2001), Kentucky (2001), and Greater Georgia (2010). 
The National Cancer Institute in conjunction with North America Association of Central 
Cancer Registries (NAACCR) guides all registries to ensure quality data content. Figure 
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1.2 represents an overall network diagram of the database that describes our research 
study. 
 
Figure 1.2: An overall network diagram describing the research study 
Prostate Cancer 
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1.3 Objectives of the Study 
In this study, the concept of parametric analysis was applied in some of the chapters. This 
methodology basically involves the identification of a probability distribution function 
that characterizes the behavior of a given variable of interest and the maximum likelihood 
estimate of the parameters. Five probability distribution functions: Weibull, Lognormal, 
Gumbel Maximum, Gamma, and Fréchet were identified and applied to statistically 
model prostate cancer tumor sizes in chapter 3 and survival times in chapter 4. 
In regards to the five probability distribution functions and their maximum likelihood 
estimates, chapter 2 gives the theory of maximum likelihood estimation for Weibull, 
Lognormal, Gumbel Maximum, Gamma, and Fréchet probability distributions together 
with their corresponding cumulative distribution function, survival function, expected 
value, and quantile estimations. In addition, the theories of three different goodness-of-fit 
tests: Kolmogorov-Smirnov, Anderson-Darling, and Chi-Squared were also discussed.  
The growth rate of prostate cancer tumor is a useful tool for understanding the history of 
prostate cancer as well as choosing a treatment option. The main objective of chapter 3 is 
to identify the growth rate of prostate cancer tumor size as a function of age. This 
analysis was performed separately for White Americans and African Americans. A non-
stationary graph of the cancerous tumor sizes as a function of age was observed for both 
races. Thus, the tumor sizes were partitioned into age groups to enhance its stationary 
behavior. Three analytical models: linear, exponential, and quadratic were fitted to the 
observed data in each partition and residual analysis performed to identify the appropriate 
fit. The first derivative of the identified model gives the growth rate of the prostate tumor 
size. In addition, the probability distribution function that characterizes the cancerous 
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tumor sizes in each age partition was identified and basic parametric estimates such as 
expected value and confidence intervals were obtained for each partition. 
Chapter 4 focuses on the evaluation of some common prostate cancer treatments. The 
treatment options considered are surgery, radiation therapy, and combination of surgery 
and radiation therapy. In addition, patients with no form of prostate cancer treatment 
were also included in this study. The evaluation was based on race and the classified 
stage of the prostate cancer. For each group studied, we identified the probability 
distribution function that characterizes the behavior of the survival times and their 
maximum likelihood estimates. The estimated parametric survival functions and basic 
parametric estimates were also obtained. The evaluation of the effectiveness of the 
treatment options was based solely on the estimated survival functions together with the 
basic parametric estimates, and expected survival time. 
Chapter 5 applies a parametric model proposed by Renshaw et al. (1996) to project the 
force of prostate cancer mortality by race and region. The model can pick up age effects, 
age independent year effects, and age dependent year effects. The main objective is to 
develop mortality models for White Americans, African Americans, and the four 
geographic regions of the United States: Northeast, Midwest, South, and West. Our 
projections show that different ages have different mortality improvement rates with the 
highest improvement occurring at younger ages and the least improvement occurring at 
older ages. 
Chapter 6 proposes possible extensions of this research study and also the introduction of 
new research ideas. 
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Chapter 2: The Probability Distribution Functions 
 
The purpose of this present chapter is to introduce the probability distribution functions 
that play an integral part in the present study. In addition to briefly discussing this 
probability distribution functions, we also summarized some of their basic properties and 
methods that were used to obtain the efficient estimates of the inherent parameters of the 
probability distribution functions. We also reviewed the goodness-of-fit methods that 
were utilized in identifying the appropriate probability distribution. Thus, this chapter is 
for the convenience of the reader, especially those in the medical profession. 
2.1 The Weibull Distribution 
The Weibull distribution is the third extreme value distribution also known as the Type 
III extreme value distribution. It is a very flexible distribution model and has a wide 
range of applications. It is very useful in modeling product or life failures in engineering 
and health sciences. It has also been applied in areas such as environmental science, 
social science, finance and other fields of study. 
2.1.1 Probability Density Function  
The 3-parameter probability density function,      for a Weibull model with shape 
parameter  , scale parameter  , and location parameter   is given by, 
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],       (2.1) 
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where    ,    , and     with expected value,           (  
 
 
). The 
corresponding cumulative density function      is given by, 
     ∫
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],   (2.2) 
and the survival function,      is given by, 
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].       (2.3) 
The 3-parameter Weibull probability density function in equation (2.1) reduces to a 2-
parameter Weibull density function when the location parameter    . The 1-parameter 
Weibull density function can be obtained by setting     in equation (2.1) and assuming 
the shape parameter   is a constant (i.e. known a priori from past experience). The 
usefulness of doing this is that it helps in analyzing data set with fewer observations. 
2.1.2 Maximum Likelihood 
For a given random dataset   {              }, the likelihood function          is 
given by, 
               {∏       
 
   }
      {    ∑       
  
   },  (2.4) 
and the log-likelihood function          is given by, 
                         ∑         
 
     
  ∑       
  
   . (2.5) 
Setting 
  
  
    
  
  
    and 
  
  
   at    ̂,    ̂, and    ̂ respectively, we obtain 
the simplified mathematical equations, 
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.        (2.8) 
Equations (2.6), (2.7), and (2.8) can be solved numerically to obtain the maximum 
likelihood estimates  ̂,  ̂, and  ̂. 
2.1.3 Quantile 
The cumulative density function (CDF) for Weibull distribution is given by equation 
(2.2). The quantile    for which  (  )      where      denotes the CDF is given by, 
 (  )       [ (
    
 
)
 
]     , 
             
 
 ⁄ . 
By the invariance property of method of maximum likelihood, 
 ̂   ̂   ̂      
 
 ̂⁄ .        (2.9) 
2.2 The Lognormal Distribution 
The lognormal distribution is a skewed distribution useful in modeling continuous 
random variables. Like the Weibull distribution, the lognormal distribution is also a 
flexible life distribution model that can empirically fit many types of failure data. This 
distribution has been widely applied in Geology, Health Science, Environmental Science, 
Social Science, and other fields of study. 
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2.2.1 Probability Density Function 
The 3-parameter probability density function,      with shape parameter  , scale 
parameter  , and location parameter   is given by, 
     
 
      √  
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[         ] },     (2.10) 
where    ,       , and     with expected value,           (  
  
 
). 
Note that, if the random variable     follows a 3-parameter lognormal distribution then 
random variable           has a normal distribution with mean   and variance   .  
The cumulative density function      for the 3-parameter lognormal distribution is given 
by, 
     ∫
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],  (2.11) 
and the survival function      is given by, 
               [
         
 
],      (2.12) 
where   denotes the standard normal CDF. The 2-parameter lognormal distribution is a 
special case of the 3-parameter model when the location parameter    . 
2.2.2 Maximum Likelihood 
Given a random sample   {              }, the likelihood function          for the 
3-parameter lognormal distribution is given by, 
         (
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)
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∑ [          ]
  
   
   
},   (2.13) 
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and the log-likelihood function          is given by, 
                  √   ∑          
∑ [          ]
  
   
   
 
   .  (2.14) 
Setting each partial derivative of equation (2.14) with respect to  ,  , and   to zero, we 
obtain three equations with three unknowns. 
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   .       (2.17) 
Solving equations (2.15), (2.16), and (2.17) numerically we obtain the maximum 
likelihood estimates  ̂,  ̂, and  ̂. 
2.2.3 Quantile 
The cumulative density function for lognormal distribution is given by equation (2.11). 
Let    be the quantile for which  (  )      denote the CDF. Then, 
 (  )   [
  (    )  
 
]     , 
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         {   [ 
       ]}. 
Applying the invariance property of method of maximum likelihood, we get, 
 ̂   ̂     { ̂   ̂[ 
       ]}.       (2.18) 
2.3 The Gumbel Distribution 
The Gumbel distribution also known as Type I extreme value distribution or log-Weibull 
distribution has two forms. One is based on the smallest extreme referred to as Minimum 
Extreme Value Type I and the other is based on the largest extreme referred to as 
Maximum Extreme Type I. Historically, the Gumbel distribution has been applied in 
environmental and reliability modeling. In reliability application, among identical parts of 
a unit that follow the same distribution, it usually models the weakest link (i.e. when the 
first part fails). In environmental, it has been used to model extreme values associated 
with flooding and rainfall. Other growing areas of application include but not limited to 
finance, insurance, telecommunication and microarray. 
2.3.1 Gumbel Maximum Probability Density Function 
The probability density function for Gumbel Maximum or Largest Extreme Distribution, 
     with location parameter  , and scale parameter   is given by, 
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)],      (2.19) 
where       , and     with expected value,          , where   = Euler’s 
constant (approximately 0.5772). The corresponding cumulative density function      is 
given by, 
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and the survival function      is given by, 
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)].     (2.21) 
2.3.2 Maximum Likelihood 
Consider the given random dataset   {              } then the log-likelihood function 
       for Gumbel Maximum is given by, 
             ∑ (
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)    .    (2.22) 
The maximum likelihood estimates  ̂ and  ̂ can be obtained by maximizing equation 
(2.22) with respect to   and   by setting 
  
  
   and 
  
  
  . Manipulating the resulting 
mathematical equations we have two equations with two unknowns. 
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     .       (2.24) 
Equations (2.23) and (2.24) can be solved numerically to obtain  ̂ and  ̂. 
2.3.3 Quantile 
Let    be the quantile for which  (  )      where      denotes the cumulative 
density function given by equation 2.20. Thus, we have, 
        [    ( 
   
 
)]     , 
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         [        ]. 
By the invariance property of method of maximum likelihood, 
 ̂   ̂   ̂  [        ].        (2.25) 
2.4 The Gamma Distribution 
2.4.1 Probability Density Function 
This distribution is used to model positively skewed data. The 3-parameter probability 
density function,      with shape parameter  , scale parameter  , and location parameter 
  is given by, 
     
 
      
            
     
 
,      (2.26) 
where    ,    ,    , and      ∫          
 
 
 with expected value,        
  . The corresponding cumulative density function      is given by, 
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,    (2.27) 
and the survival function      is given by, 
              
    
 
   
    
,       (2.28) 
where       ∫  
      
 
 
   is the lower incomplete gamma function. The survival 
function has no closed form expression. However, there exist algorithms for its 
computation. When the location parameter,    , we obtain a 2-parameter gamma 
distribution. 
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2.4.2 Maximum Likelihood 
Given a random sample,   {              } then the likelihood function for the 3-
parameter gamma distribution          is given by, 
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   ,  (2.29) 
and the log-likelihood function          is given by, 
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The maximum likelihood estimates can be obtained by setting 
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   at    ̂,    ̂, and    ̂ respectively. 
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Substituting equation (2.31) into equation (2.32) and simplifying, we have, 
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where          ⁄  is called the digamma function defined as the logarithmic derivative 
of the gamma function. 
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Equations (2.31), (2.33), and (2.34) can be solved numerically to obtain the maximum 
likelihood estimates  ̂,  ̂, and  ̂. 
2.4.3 Quantile 
The cumulative density function for a gamma distribution is defined by equation (2.27). 
Define    as the quantile for which  (  )      where       denotes the CDF. Then, 
     
     
 
   
    
    . 
Here, the solution for    is not analytically tractable. However, there exist numerical 
algorithms for its computation. 
2.5 The Fréchet Distribution 
The Fréchet distribution also referred to as Maximum Extreme Value Type II is a special 
case of Generalized Extreme Value distribution. This distribution has been applied in 
areas like hydrology, environmental, finance, chemistry, etc. 
2.5.1 Probability Density Function 
The 3-parameter probability density function for Fréchet Distribution,      with shape 
parameter  , scale parameter  , and location parameter  , is given by, 
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],       (2.35) 
where    ,    , and     with expected value,           (  
 
 
) for    . 
The corresponding cumulative density function      is given by, 
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and the survival function      is given by, 
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Equation (2.35) reduces to 2-parameter Fréchet distribution when    . 
2.5.2 Maximum Likelihood 
Given a random dataset,   {              } then the likelihood function for the 3-
parameter Fréchet distribution          is given by, 
              {∏       }
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and the log-likelihood function          is given by, 
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Setting 
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   at    ̂,    ̂, and    ̂ respectively, we obtain 
the simplified mathematical equations, 
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Equations (2.40), (2.41), and (2.42) can be solved numerically to obtain the maximum 
likelihood estimates  ̂,  ̂, and  ̂. 
2.5.3 Quantile 
The cumulative density function (CDF) for Fréchet distribution is given by equation 
(2.36). The quantile    for which  (  )      where      denotes the CDF is given 
by, 
         [ (
 
   
)
 
]     , 
       [        ]
  
 ⁄ . 
By the invariance property of method of maximum likelihood, 
 ̂   ̂   ̂[        ]
  
 ̂⁄ .       (2.43) 
2.6 Goodness-of-Fit 
A probability-probability (P-P) and quantile-quantile (Q-Q) plot together with 
Kolmogorov-Smirnov, Anderson-Darling, and Chi-Squared tests would be used to assess 
the goodness-of-fit. 
The P-P plot is a graphical tool used to determine how well a specific distribution fits an 
observed data. The plot compares the empirical cumulative distribution function of the 
data with the theoretical cumulative distribution function. The location and scale 
parameters of the distribution are required to evaluate the cumulative distribution 
function of the ordered data set. This plot will be approximately linear if the specified 
theoretical distribution reasonably describes the distribution of the observed data. 
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The Q-Q plot is another graphical tool used to verify how well a specific distribution fits 
an observed data. This plot is a graph of the quantiles of the data distribution versus the 
quantiles of a standardized theoretical distribution from a specified family of 
distributions. Here, the location and scale parameters are not required to be specified. The 
theoretical quantiles are computed from a standardized distribution within the specified 
family. A linear pattern indicates that the specified family is a good fit for the data with 
the intercept representing the estimated location parameter and the slope representing the 
estimated scale parameter. 
Kolmogorov-Smirnov test is a statistical test used to decide if an observed data comes 
from a hypothesized continuous distribution. It is based on the empirical cumulative 
distribution function. Given a dataset   {          } from a continuous distribution 
with cumulative distribution function     , the empirical cumulative distribution function 
denoted by       is defined by, 
      
 
 
                           . 
The Kolmogorov-Smirnov statistic   which is based on the largest vertical difference 
between the cumulative distribution function and the empirical cumulative distribution 
function is defined as, 
   
   
 
|          |. 
This statistic is calculated under the null hypothesis that the data follow the specified 
distribution. The hypothesis is rejected at the    level of significance if the statistic   is 
greater than the critical value of the theoretical distribution. 
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The Anderson-Darling test is another statistical test that compares the fit of the observed 
cumulative distribution to the expected cumulative distribution function. This test gives 
more weight to the tails than the Kolmogorov-Smirnov test. Given a dataset   
{          } with cumulative distribution function     , the Anderson-Darling statistic 
denoted by    is defined as, 
      ∑
      
 
[                       ]
 
   . 
This statistic is computed under the null hypothesis that the data follow the specified 
distribution. The hypothesis is rejected at the    level of significance if the statistic    is 
greater than the critical value of the theoretical distribution. 
The Chi-Squared goodness-of-fit test is a statistical test that requires observed data be 
grouped into intervals of equal width with each group representing a cell. There is no 
optimal choice for the number of cells. However, each cell is required to contain at least 
five data points. Given a dataset   {          } with cumulative distribution function 
    , the Chi-Squared statistic denoted by    is defined as, 
   ∑
       
 
  
 
   , 
where    is the observed frequency for cell  , and    is the expected frequency for cell   
calculated as, 
              , 
where,    and    are the limits for cell  . The Chi-Squared statistic is calculated under the 
null hypothesis that the data follow the specified distribution. The hypothesis is rejected 
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at the    level of significance if the statistic    is greater than the critical value 
         
 . 
2.7 Conclusion 
In this chapter, we reviewed the basic aspects of the probability distribution functions that 
will be utilized in chapter 3 and/or chapter 4 of this study, namely; Weibull, Lognormal, 
Gumbel Maximum, Gamma, and Fréchet probability distributions. In addition, we have 
briefly discussed the statistical methods that will be used to appropriately identify which 
of the above probability distribution functions best characterize the behavior of the 
subject response. 
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Chapter 3: Mathematical Characterization of Prostate Cancer Tumor Size as a 
Function of Age 
3.1 Introduction 
The growth rate of prostate cancer tumor is an important aspect to understanding the 
natural history of prostate cancer. In respect to this objective, identifying a mathematical 
behavior of the tumor growth is equally essential. Several studies have showed that the 
average tumor size is statistically different among race. In fact, Chan (2012) in his paper 
“Parametric Analysis of Prostate Cancer” showed that the average tumor size for White 
Americans is statistically larger than African Americans. Balducci (2001) in his paper 
also mentioned that with the aging of the population, there is an increasing problem of 
cancer in older persons. That is, the biological behavior of cancer worsens with aging. 
In this study, scatter plots of actual data not only reveal differences in the behavior of the 
tumor growth by race but also reveal that the growth varies by age. Thus, we would 
proceed to perform the analysis for White and African Americans separately. 
3.2 Data 
A total of 479,204 records of prostate cancer patients collected from 1973 to 2007 were 
obtained from the SEER database. 23,610 of these records have known tumor size with 
23,573 of the tumors being malignant and 37 benign. This analysis focuses on only the 
malignant tumors measured in millimeters. An extended detail of the data is given by 
Figure 3.1. 
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Figure 3.1: Schematic diagram of prostate cancer patients with malignant tumors 
Using information from this data, we address the following questions: 
 What age intervals have the same analytical form of the average tumor sizes? 
 What mathematical expression describes the behavior of the average tumor sizes 
in each age interval? 
 What is the estimated rate of change in tumor growth for each age partition? 
 What probability distribution function characterizes the behavior of the malignant 
tumors in each age partition and their corresponding 95% confident limits? 
3.3 Mathematical Characterization for White Americans 
Three mathematical functions: exponential, linear, and quadratic were fitted to the 
observed data and residual analysis performed to evaluate the quality of the fitted models. 
Suppose    {          } represent the observed average tumor size,  ̂  
{ ̂   ̂     ̂ } represent the corresponding estimated average tumor size under a 
Prostate cancer patients 
in the database 
(479204) 
Patients with malignant 
tumor size               
(23,573) 
White   
Americans 
(20,614) 
African 
Americans  
(1,755) 
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specified model, and we define the residual     ̂    , then the residual mean   ̅ is 
estimated as, 
 ̅  
∑   
 
   
 
.  
The residual mean   ̅can be interpreted as a measure of goodness-of-fit. A residual mean 
close to zero is an indication of a good fit. 
The selected model can be improved by including the estimated residual mean. For 
example, if  ̅   , then the model is overestimating and can be improved by subtracting 
the estimated residual mean. On the other hand, if  ̅   , then the model is 
underestimating and can be improved by adding the estimated residual mean. 
The first order derivative of the improved model represents the rate of change in tumor 
growth. For exponential and quadratic models, the rate of change in tumor growth will be 
obtained by taking the average of all the estimated rates in that age interval. Higher order 
models were not considered because residual analysis does not support the quality of the 
models as well as the estimated growth rates have no relevant medical interpretation. 
A scatter plot of average tumor size as a function of age for all White Americans with 
malignant tumor is given by Figure 3.2. The graph is not stationary over the entire age 
(i.e. 36-98 years). Thus, we partitioned using plus one time point process while observing 
changes in trend and accounting for the quality of the model through residual analysis. 
Using this process, we arrived at seven age partitions as follows: 36-45 years, 46-54 
years, 55-62 years, 63-75 years, 76-83 years, 84-89 years, and 90-98 years. 
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Figure 3.2: Scatter plot of average tumor size for White Americans Age 36-98 
3.3.1 First Age Interval: Age 36-45 Years 
A plot of average tumor size as a function of age in this age interval is given by Figure 
3.3. Visually, a linear or quadratic model may seem appropriate for this group. However, 
linear, exponential, and quadratic models were fitted to the observed data and residual 
analysis performed gave a residual mean of -0.82093 for exponential, -0.00135 for linear, 
and -0.00015 for quadratic. This attests that quadratic model better explains this behavior. 
The analytical structure that describes the behavior of the average tumor sizes in this age 
interval is given by, 
              
                                            . 
A residual mean of -0.00015 indicates that the model is underestimating and can be 
improved by adding 0.00015 to the model. However, this model was not improved solely 
because the residual mean is relatively small. 
The first derivative of       with respect to age   is given by, 
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                                               . 
The above function represents the model for estimating the rate of change in prostate 
tumor size as a function of age for this interval. The average of the resulting estimates in 
the domain of the function represents the rate of change in tumor growth for patient’s age 
36 to 45 years. This average is approximately 1.26. Thus, the estimated rate of change in 
prostate tumor growth is approximately 1.26 for this age interval. 
 
Figure 3.3: Fitted scatter plot of average tumor size for White Americans Age 36-45 
3.3.2 Second Age Interval: Age 46-54 Years 
The plot of average tumor size as a function of age for this interval is given by Figure 3.4. 
Visually, an open up quadratic model may seem appropriate for this age group. However, 
exponential, linear, and quadratic models were fitted to the observed data and residual 
analysis performed to evaluate the quality of the fitted models. The residual analysis 
produced a residual mean of 0.00827 for exponential, -0.00163 for linear, and -0.00033 
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for quadratic. The results of the residual analysis support our visual observation. The 
mathematical function that describes this behavior is given by, 
             
                                          . 
The model was not improved due to the relatively small residual mean. Estimates of the 
rate of change in tumor size for patients in this age group are determined by 
differentiating       with respect to age   and evaluating the resulting linear function in 
the given domain. The average of these estimates is approximately 0.153. This represents 
the rate of change in tumor growth for this age interval. 
 
Figure 3.4: Fitted scatter plot of average tumor size for White Americans Age 46-54 
3.3.3 Third Age Interval: Age 55-62 Years 
A fitted scatter plot of average tumor size as a function of age for patient’s age 55 to 62 
years is given by Figure 3.5. Three mathematical functions: linear, exponential, and 
quadratic were fitted to the observed data and evaluated using residual analysis. The 
results of the analysis proved that an open up quadratic model was appropriate to describe 
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the behavior of the average tumor sizes in this age group. We obtained a residual mean of 
-0.04766 for exponential, 0.00105 for linear, and -0.00025 for quadratic. The 
mathematical function that characterize the quadratic behavior is given by, 
             
                                       . 
The model was not improved due to the relatively small residual mean. The derivative of 
the function      , evaluated at age   in the domain         gives the estimates of 
the rate of change in tumor size for patients in this age interval. The average of these 
estimates is approximately 0.0784. This represents the estimated rate of change in tumor 
growth for prostate cancer patients in this age interval. 
 
Figure 3.5: Fitted scatter plot of average tumor size for White Americans Age 55-62 
3.3.4 Fourth Age Interval: Age 63-75 Years 
Figure 3.6 represents a graphical display of average tumor size as a function of age for 
patient’s age 63 to 75 years. Visually, a linear model with a positive slope or an open 
down quadratic model may seem appropriate to describe this behavior. However, residual 
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analysis performed on three fitted models: linear, quadratic, and exponential revealed a 
quadratic structure for the behavior of the average tumor sizes in this age interval. The 
analysis produced a residual mean of 0.04112 for exponential, -0.00078 for linear, and 
0.000115 for quadratic. The quadratic function that characterize this behavior is given by, 
              
                                 . 
A residual mean of 0.000115 is relatively small. Thus, the model needs no improvement. 
The rate of change in tumor growth for this age group is obtained by differentiating the 
quadratic function      , evaluating the resulting function at age   in the given domain, 
and the average of these estimates represents the estimated rate of change in tumor 
growth for this age group. The resulting growth rate is approximately 0.0604. 
 
Figure 3.6: Fitted scatter plot of average tumor size for White Americans Age 63-75 
3.3.5 Fifth Age Interval: Age 76-83 Years 
A graphical display of average tumor size as a function of age for patient’s age 76-83 
years is given by Figure 3.7. Linear, quadratic, and exponential models were fitted to the 
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observed data and residual analysis performed to evaluate the quality of the models. The 
analysis attests that a quadratic model gives a much better description of the behavior of 
the average cancerous tumor sizes in this age interval with a residual mean of -1.5×10
-13
. 
The residual mean under exponential and linear functions are -0.13948 and 0.00045, 
respectively. The analytical structure of the quadratic model is given by, 
             
                                  . 
Due to the relatively small residual mean, the selected model was not improved. The 
derivative of the quadratic function      , evaluated at age   in the domain of the function 
gives estimates of the rate of change in tumor size for this age group. The average of the 
estimates is approximately 0.7125. This represents the rate of change in tumor growth for 
patient’s age 76 to 83 years. 
 
Figure 3.7: Fitted scatter plot of average tumor size for White Americans Age 76-83 
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3.3.6 Sixth Age Interval: Age 84-89 Years 
A scatter plot of average tumor size as a function of age in this age interval is given by 
Figure 3.8. Visually, an open up quadratic model may seem appropriate for this group of 
cancer patients. Residual analysis performed on the three fitted models; linear, quadratic, 
and exponential confirmed that a quadratic model explains the behavior of the average 
tumor sizes of this group of patients. The analysis produced a residual mean of -0.14814 
for exponential, 0.0029 for linear, and -0.000417 for quadratic. The analytical structure 
that supports the selected quadratic model is given by, 
             
                                    . 
 
Figure 3.8: Fitted scatter plot of average tumor size for White Americans Age 84-89 
Model improvement was not performed due to the relatively small residual mean. The 
estimated rate of change in tumor size is computed by differentiating the quadratic 
function      , evaluating the resulting expression at age   in the given domain, and 
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taking the average of the estimates. Thus, the estimated rate of change in tumor growth is 
approximately 0.5525 for patient’s age 84 to 89 years. 
3.3.7 Seventh Age Interval: Age 90-98 Years 
Figure 3.9 represent a graphical display of average tumor size as a function of age for age 
group 90 to 98 years. The observed trend clearly suggest an open up quadratic model and 
residual analysis attest to the quality of this observed trend with a residual mean of 
0.0005167. The residual mean under exponential and linear functions are -0.68675 and 
0.003183, respectively. The mathematical function that characterize the quadratic trend is 
given by, 
             
                                   . 
 
Figure 3.9: Fitted scatter plot of average tumor size for White Americans Age 90-98 
Model improvement was not performed due to the relatively small residual mean. When 
we differentiate the function       with respect to age  , evaluate the resulting expression 
at age   in the given domain and take the average of the estimates, we obtain the 
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estimated rate of change in tumor growth for patients in this age group. The estimate is 
approximately 0.5851. 
3.3.8 Summary 
A summary of the estimated rate of change in prostate cancer tumor growth as a function 
of age for White Americans are given in Table 3.1. 
Table 3.1: Estimated rate of prostate cancer tumor growth for White Americans 
Age Interval (in years) 36-45 46-54 55-62 63-75 76-83 84-89 90-98 
Estimated Rate (in mm) 1.26 0.153 0.0784 0.0604 0.7125 0.5525 0.5851 
 
From the table, we can infer that the growth rate of prostate cancer tumor size for White 
Americans is relatively larger for individuals below age 55 years and individuals above 
age 75 years with the greatest rate occurring below age 46 years. The least estimated rates 
occur at age 55 to 75 years. 
3.4 Mathematical Characterization for African Americans 
A scatter plot of average tumor size as a function of age for all African Americans in the 
database is given by Figure 3.10. 
The graph is not stationary over the entire age (i.e. 40-93 years). Thus, we partitioned 
using plus one time point process while observing changes in trend and accounting for 
the quality of the model through residual analysis. This resulted in seven age partitions as 
follows: 40-47 years, 48-58 years, 59-67 years, 68-74 years, 75-81 years, 82-86 years, 
and 87-93 years. 
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Figure 3.10: Scatter plot of average tumor size for African Americans Age 40-93 
3.4.1 First Age Interval: Age 40-47 Years 
A scatter plot of average tumor size as a function of age for cancer patients in this age 
interval is given by Figure 3.11. Linear, quadratic, and exponential models were fitted to 
the observed data and residual analysis performed. The residual analysis produced a 
residual mean of -0.91216 for exponential, -0.00025 for linear, and 1.088×10
-13
 for 
quadratic. The results of the analysis proved that a quadratic model better describes the 
behavior of the average tumor sizes for this age interval. The analytical structure that 
describes this behavior is given by the mathematical function, 
             
                                     . 
The estimated residual mean indicate that the model is overestimating and therefore can 
be improved by subtracting 1.088×10
-13
 from the model. However, this estimate is very 
small and will not be incorporated to improve the model. The estimated rate of change in 
tumor growth is obtained by differentiating      , evaluating the resulting function at age 
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  in the given domain, and taking the average of these estimates. The resulting estimate is 
approximately 0.3052. 
 
Figure 3.11: Fitted scatter plot of average tumor size for African Americans Age 40-47 
3.4.2 Second Age Interval: Age 48-58 Years 
A plot of average tumor size as a function of age for this age group is given by Figure 
3.12. Visually, a linear model may seem appropriate for this behavior. Residual analysis 
of fitted models (linear, quadratic, and exponential) confirmed that a linear model really 
describe the behavior of the tumors with a residual mean of -0.0015. The residual mean 
under exponential and quadratic functions are -0.03606 and 0.11812, respectively. The 
selected linear model was improved by adding 0.0015. The mathematical function that 
represents the improved linear behavior is given by, 
                                      . 
The derivative of the linear function       is a constant. Thus, the estimated rate of 
change in tumor growth for patient’s age 48 to 58 years is approximately 0.3577. 
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Figure 3.12: Fitted scatter plot of average tumor size for African Americans Age 48-58 
3.4.3 Third Age Interval: Age 59-67 Years 
A graphical display of average tumor size as a function of age for cancer patient’s age 59 
to 67 years is given by Figure 3.13. Exponential, linear, and quadratic models were fitted 
to the data and residual analysis performed to evaluate the quality of the fitted models. 
The evaluation revealed that an open down quadratic model appropriately describe the 
behavior of these tumor sizes. We obtained a residual mean of -0.00243 for linear, 
0.098132 for exponential, and 0.00033 for quadratic. The mathematical function that 
supports the quadratic behavior is given by, 
            
                                  . 
Model improvement was not performed due to the relatively small residual mean. 
Differentiating        with respect to age   and evaluated at age   in the given domain 
gives the estimates of the rate of change in tumor size for this age group. The average of 
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these estimates represents the rate of change in tumor growth for this interval. The 
resulting estimate for this age group is approximately 0.249. 
 
Figure 3.13: Fitted scatter plot of average tumor size for African Americans Age 59-67 
3.4.4 Fourth Age Interval: Age 68-74 Years 
Figure 3.14 represent a graphical display of average tumor size as a function of age for 
cancer patient’s age 68 to 74 years. Quadratic, linear, and exponential models were fitted 
to the observed data. Evaluation of the residual analysis proved that an open up quadratic 
model gives a better description of the data with a residual mean of -0.000143. The 
estimated residual mean under exponential is -0.91727 and for linear is -0.00204. The 
analytical structure that describes the quadratic behavior is given by, 
              
                                    . 
No improvements were made to this model due to the relatively small residual mean. The 
derivative of        gives a function in terms of  . Evaluating the resulting function at age 
  in the given domain gives estimates of the rate of change in tumor size for this age 
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interval. The average of these estimates represents the rate of change in tumor growth for 
patient’s age 68 to 74 years. The estimated average is approximately 0.1138. 
 
Figure 3.14: Fitted scatter plot of average tumor size for African Americans Age 68-74 
3.4.5 Fifth Age Interval: Age 75-81 Years 
A fitted plot of average tumor size as a function of age is given by Figure 3.15 for age 
interval 75 to 81 years. Visually, an open up quadratic trend may seem appropriate for 
this age group. Evaluation of the residual analysis really attests to the observed tend. The 
residual analysis produced a residual mean of -0.20312 for exponential, -0.00352 for 
linear, and -0.0002 for quadratic. The mathematical function that characterize this 
quadratic trend is given by, 
              
                                    . 
Model improvement was not performed due to the relatively small residual mean. The 
derivative of the function        with respect to age  , evaluated at each age   in the given 
domain of the function, and average of these estimates gives an approximate estimate for 
 42 
 
the rate of change in tumor growth for this age group. Thus, the estimated growth rate is 
approximately 0.1313 for patients in this age group. 
 
Figure 3.15: Fitted scatter plot of average tumor size for African Americans Age 75-81 
3.4.6 Sixth Age Interval: Age 82-86 Years 
A scatter plot of average tumor size as a function of age for patient’s age 82 to 86 years is 
given by Figure 3.16. Visually, a linear or exponential model may seem appropriate for 
this age interval. Residual analysis performed on fitted linear, quadratic, and exponential 
models revealed that an exponential model explains the behavior of the tumors much 
better than a linear model with a residual mean of 0.000104 for exponential and -0.002 
for linear. The residual mean under quadratic is -0.3202. The mathematical function that 
supports the exponential behavior is given by, 
                 
                               . 
The model was not improved due to the relatively small residual mean. The derivative of 
       is given by, 
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Using the above function, we compute estimates of the rate of change in tumor size as a 
function of age in the given domain. The average of these estimates represents the 
estimated rate of change in tumor growth for patient’s age 82 to 86 years. This estimate is 
approximately 2.897. 
 
Figure 3.16: Fitted scatter plot of average tumor size for African Americans Age 82-86 
3.4.7 Seventh Age Interval: Age 87-93 Years 
A graphical display of average tumor size as a function of age for cancer patients in this 
age interval is given by Figure 3.17. Visually, an open up quadratic model may seem 
appropriate for the behavior of the average tumor sizes in this interval. Residual analysis 
performed really confirmed this behavior. We obtained a residual mean of -3.77379 for 
exponential, -0.0004 for linear, and 1.441×10
-12
 for quadratic. The mathematical structure 
that describes this open up quadratic behavior is given by, 
            
                                    . 
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With a very small residual mean of 1.441×10
-12
, the resulting quadratic model was not 
improved. Differentiating the quadratic function       , and evaluating the resulting 
function at age   in the defined domain gives estimates of the rate of change in tumor size 
for patients in this age group. The average of these estimates is approximately 3.07. This 
represents the estimated rate of change in tumor growth for patient’s age 87 to 93 years. 
 
Figure 3.17: Fitted scatter plot of average tumor size for African Americans Age 87-93 
3.4.8 Summary 
A summary of the estimated rate of change in prostate cancer tumor growth as a function 
of age for African Americans are given in Table 3.2. 
Table 3.2: Estimated rate of prostate cancer tumor growth for African Americans 
Age Interval (in years) 40-47 48-58 59-67 68-74 75-81 82-86 87-93 
Estimated Rate (in mm) 0.3052 0.3577 0.249 0.1138 0.1313 2.897 3.07 
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From the table, we can infer that the growth rate of prostate cancer tumor size for African 
Americans is relatively larger across all age groups with the greatest estimated rates 
occurring above age 81 years and the least estimated rates occurring at age 68 to 81 
years. 
3.5 Probabilistic Characterization of the Malignant Tumor Sizes 
Different classical distributions were fitted to the observed data in each age partition to 
identify the probability distribution function that characterizes the behavior of the 
malignant tumors. A P-P and Q-Q plot together with three commonly used goodness-of-
fit tests; Kolmogorov-Smirnov, Anderson-Darling, and Chi-Squared were examined to 
verify the goodness-of-fit. Based on the identified probability distribution function, the 
corresponding maximum likelihood estimates of the parameters were obtained with their 
corresponding 95% confidence limits. Of all the age groups studied, we identified four 
probability distribution functions: Weibull, Lognormal, Gamma, and Fréchet. The theory 
of their maximum likelihood and quantile estimations has been discussed in chapter 2. 
3.5.1 Probabilistic Behavior for White Americans 
Classical distributions were fitted to the observed tumor sizes in each age partition and 
goodness-of-fit test performed to determine the appropriate distributional forms that 
characterize the behavior of the tumor sizes.  
Lognormal probability distribution function was identified for the first age group 36-45 
years with maximum likelihood estimates given by shape parameter  ̂        , scale 
parameter  ̂        , and location parameter  ̂         . The actual form of the 
probability density function as given in chapter 2 is of the form, 
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The graph of the identified lognormal density function with the inherent parameter 
estimates and the corresponding P-P plot are given by Figure 3.18. The P-P plot follows a 
reasonable straight line pattern indicating that the 3P-lognormal density function is a 
good fit for the observed data. This was consistent with the results of the three formal 
goodness-of-fit tests. 
 
Figure 3.18: Fitted 3P-lognormal probability density function and P-P plot 
From the identified probability distribution function and the parameter estimates, we can 
estimate the expected cancerous tumor size and corresponding 95% confidence limits for 
this age group. Recall from chapter 2, the analytical form for estimating the expected 
value and the confidence limits under lognormal probability distribution are given by, 
      ̂     ( ̂  
 ̂ 
 
)  and   ̂   ̂     { ̂   ̂[ 
       ]}, 
respectively. Thus, the estimates are computed as follows: 
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Expected tumor size,                 (       
       
 
)          . 
Lower confidence limit,  ̂                                           . 
Upper confidence limit,  ̂                                           . 
Thus,                            , where   represents the true mean 
tumor size for White Americans age 36 to 45 years. 
The above process was again followed to address the remaining age groups. Following 
this, we identified Fréchet probability distribution function for age groups 46-54 years, 
55-62 years, 76-83 years, and 90-98 years; and Weibull for age groups 63-75 years, and 
84-89 years with details of the probability distributions given in Table 3.3.  
Table 3.3: Probabilistic characterization of malignant tumor sizes for White Americans 
Age Interval  
(Years) PDF MLE 
Expected Value 
(Standard Deviation) 
95% Confidence 
 Interval 
36-45 
 
3P-Lognormal  ̂         
 ̂         
 ̂          
11.877 (5.2049)                
20.394* 
46-54 
 
2P-Frechet  ̂         
 ̂         
14.958 (0.5549)               ) 
2.146* 
55-62 
 
2P-Frechet  ̂         
 ̂         
15.135 (0.8027)                 
3.098* 
63-75 
 
2P-Weibull  ̂       
 ̂       
16.023 (0.397)                 
1.543* 
76-83 
 
2P-Frechet  ̂         
 ̂         
12.767 (3.4885)                 
12.7423* 
84-89 
 
2P-Weibull  ̂         
 ̂         
8.8961 (2.0329)                 
7.9162* 
90-98 
 
2P-Frechet  ̂         
 ̂        
6.851 (N|A)                
26.904* 
*Confidence range = upper confidence limit – lower confidence limit 
Notice that, there is a high variability in tumor size for patients below 46 years and above 
75 years of age. This was evident in the estimated standard deviation as well as the 
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confidence range. The standard deviation for patient’s age 90-98 years did not converge 
to a real number. 
3.5.2 Probabilistic Behavior for African Americans 
Here, Gamma distribution was identified for age group 40-47 years; Weibull was 
identified for age groups 48-58 years, 59-67 years, 68-74 years, 82-86 years, and 87-93 
years; and Fréchet was identified for age group 75-81 years. The maximum likelihood 
estimates of the parameters, expected tumor sizes with their corresponding 95% 
confidence limits are given in Table 3.4. 
By way of illustration, let’s consider age group 75-81 years with underlying Fréchet 
probability density function with inherent maximum likelihood estimates given by shape 
parameter  ̂        , scale parameter  ̂        , and location parameter  ̂   . The 
actual form of the probability density function as given in chapter 2 is of the form, 
 (   ̂  ̂  ̂)  {
 ̂
 ̂
(
 ̂
   ̂
)
 ̂  
   [ (
 ̂
   ̂
)
 ̂
]
               
       ̂. 
The graph of the identified Fréchet density function with the inherent parameter estimates 
and the corresponding P-P plot are given by Figure 3.19. The P-P plot follows a 
reasonable straight line pattern indicating that the 2P-Fréchet density function is a good 
fit for the observed data. This was consistent with the results of the three formal 
goodness-of-fit tests. 
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Figure 3.19: Fitted 2P-Fréchet probability density function and P-P plot 
From the identified Fréchet probability distribution function and the parameter estimates, 
we can estimate the expected cancerous tumor size and corresponding 95% confidence 
limits for this age group. Recall from chapter 2, the analytical form for estimating the 
expected value and the confidence limits under Fréchet probability distribution are given 
by, 
      ̂   ̂ (  
 
 ̂
)  and   ̂   ̂   ̂[        ]
   ̂⁄ , 
respectively. Thus, the estimates are computed as follows: 
Expected tumor size,                (  
 
      
)         . 
Lower confidence limit,  ̂          [        ]
        ⁄          . 
Upper confidence limit,  ̂          [        ]
        ⁄          . 
Thus,                           , where   represents the true mean 
tumor size for African Americans age 75 to 81 years. Following the above process, we 
have identified the probability distribution functions that characterize the behavior of the 
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malignant tumor sizes for age groups 40-47 years, 48-58 years, 59-67 years, 68-74 years, 
82-86 years and 87-93 years and obtained their corresponding estimates as given in Table 
3.4. 
Table 3.4: Probabilistic characterization of malignant tumor sizes for African Americans 
Age Interval  
(Years) PDF MLE 
Expected Value 
(Standard Deviation) 
95% Confidence  
Interval 
40-47 
 
3P-Gamma  ̂         
 ̂         
 ̂          
12.107 (4.1223)                 
16.1516* 
48-58 
 
3P-Weibull  ̂         
 ̂         
 ̂        
13.194 (1.7091)                 
6.6679* 
59-67 
 
2P-Weibull  ̂         
 ̂         
12.757 (2.0355)                 
7.9471* 
68-74 
 
2P-Weibull  ̂         
 ̂         
11.147 (1.9069)                 
7.4433* 
75-81 
 
2P-Frechet  ̂         
 ̂         
10.77 (2.7113)                 
9.9767* 
82-86 
 
3P-Weibull  ̂         
 ̂         
 ̂       
12.944 (13.452)                
39.205* 
87-93 
 
2P-Weibull  ̂         
 ̂         
8.9314 (15.405)                 
51.5645* 
*Confidence range = upper confidence limit – lower confidence limit 
Results from Table 3.4 show a high variability in tumor size among all the age groups. 
However, it is more evident among patients below 48 years and above 81 years of age as 
revealed by their estimated standard deviations and confidence range. 
3.6 Comparison of White and African Americans 
Based on the two analyses, we have observed the following. 
 The estimated growth rates in prostate tumor size are relatively higher in African 
Americans than White Americans. This is evident at age 46 to 75 years and over 
81 years. 
 In terms of variability, the above relationship was again observed. 
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 If we define  ̅  as the average of the expected tumor sizes in Table 3.3 and  ̅   
as the average of the expected tumor sizes in Table 3.4, then  ̅          and 
 ̅          . Thus, the average tumor size for White Americans is relatively 
larger than African Americans. This is consistent with the results of Chan (2012). 
3.7 Conclusion 
Research has shown that the disease cancer varies by race, age of patient and other 
prognostic factors. This study has affirmed that the analytical growth behavior of prostate 
cancerous tumor size also vary by race and age of the patient.  
Of all the fourteen age partitions studied there were five open up and two open down 
quadratic growth behaviors for White Americans; four open up and one open down 
quadratic growth behaviors for African Americans; one exponential growth behavior and 
one linear growth behavior with a positive slope also for African Americans. The 
derivative of the developed models as a function of age represents the rate of change in 
prostate cancer tumor size. 
Variations in these estimated growth rates make it difficult to determine any specific 
pattern in the levels of growth. However, the estimated growth rates are relatively higher 
in younger patients and older patients for both White and African Americans. 
Comparatively, the growth rates are relatively higher in African Americans than White 
Americans at age 46 to 75 years and over 81 years. 
We have identified the probability distribution functions that characterize the behavior of 
the malignant tumor sizes in each age partition. This is very useful information because it 
provides the probabilistic behavior of the malignant tumors with some degree of 
 52 
 
assurance. For example, every 95 out of 100 prostate cancer patients age 79 years the 
expected tumor size will be between 8.8547 and 21.597 for White Americans and 
between 7.6643 and 17.641 for African Americans. Thus, at this age, we can expect the 
prostate tumor size to be relatively larger among White Americans than African 
Americans. 
3.8 Contributions 
In this chapter we have addressed some important issues regarding prostate cancer. 
 We have identified seven age partitions under each race that describes the 
behavior of the prostate cancerous tumor sizes for White Americans and African 
Americans. 
 In each age partition, we have developed a mathematical model that describes the 
behavior of the prostate cancerous tumor sizes. 
 The rate of change in prostate tumor size can be estimated using the models. 
 The estimated growth rates in prostate tumor size are relatively higher in African 
Americans than White Americans. This is evident at age 46 to 75 years and over 
81 years. This is useful information for both the patient and physician. 
 We have also identified the probability distribution functions that characterize the 
behavior of the malignant tumor sizes for White Americans and African 
Americans in each age group. 
 Utilizing this information, we can obtain the expected value, confidence limits, 
and confidence range. 
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Chapter 4: Statistical Evaluation of Different Prostate Cancer Treatments 
 
4.1 Introduction 
The first case of prostate cancer was described by J. Adams, a surgeon at The London 
Hospital, in 1853. He discovered this by histological examination and noted that this was 
a rare disease [Denmeade & Isaacs, 2002]. One hundred and fifty-nine years down the 
line, prostate cancer has become a significant health issue partly because it is the most 
commonly diagnosed cancer in men with a high percentage of recorded deaths annually. 
This year alone, the estimated new cases of prostate cancer in the United States are 
approximately 238,590 with an estimated 29, 720 deaths representing about 12.5% of 
estimated deaths by prostate cancer diagnosis [American Cancer Society & National 
Cancer Institute].  
The increase in the incidence of prostate cancer diagnosis has led to several remarkable 
changes in treatment over the past century. Androgen-ablation therapy which involves 
medical castration with oral oestrogens was one of the first effective treatments for any 
cancer. This therapy dates back to the eighteen century. Initially, several patients 
responded to the androgen-ablation treatment but over time developed fatal androgen-
independent disease [Feldman & Feldman, 2001]. This realization led to the introduction 
of hormone treatment and chemotherapy. The hormone treatment was either to block the 
production of adrenal androgen or prevent androgen interaction within the target tissue. 
Chemotherapy treatment was mainly used for hormone refractory prostate cancer. 
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Different clinical trials involving some agents of chemotherapy (mitoxantrone and 
corticosteroid, estramustine, vincristine, etoposide, doxorubicin, and the taxanes 
paclitaxel and docetaxel) emerged from 1950-1975 [Hudes, et al., 1992 & 1997; Pienta, 
et al., 1994; Sella, et al., 1994; Savarese, et al., 2001]. Results indicate survival advantage 
in patients treated with these chemotherapy combinations [Denmeade & Isaacs, 2002]. 
In the twentieth century, prostatectomy and radiation therapy emerged. Prostatectomy 
involves the use of surgical and radiological techniques to treat prostate cancer. The first 
systematic technique for removal of the prostate was by Hugh Hampton Young in 1904 at 
the Johns Hopkins Hospital [Young, 1905] and the next surgical advancement was 
introduced by Terrence Millin in 1945 [Millin, 1945]. This treatment was not very 
common because most patients were left impotent by the procedure. However, in 1983, 
Patrick Walsh developed a modified technique to control bleeding allowing erectile 
function and sexual potency to be maintained [Walsh, Lepor, & Eggleston, 1983]. The 
first report on the use of radiation to treat prostate cancer involved the introduction of 
radium sources as an alternative to surgery [Denmeade & Isaacs, 2002; Young, 1917]. 
This technique was initially difficult to perform and uncomfortable for patients. It lost 
popularity as a treatment for prostate cancer in the 1940s but returned in the 1950s after 
the introduction of higher-energy cobalt machines that could penetrate to deeper levels. 
Over the years, other radioisotopes have been developed.  
Currently, there are several treatments recommended by physicians for prostate cancer. 
The most common types are surgery, radiation therapy, combination of surgery and 
radiation therapy, and hormone therapy. However, in this analysis, we will focus on the 
evaluation of the treatment types: surgery, radiation therapy, combination of surgery and 
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radiation therapy, and no treatment. No treatment involves the group of patients who did 
not receive any form of cancer related treatment during the period under study. 
4.2 Data Description 
Approximately 500,788 records of prostate cancer patients collected from 1973 to 2008 
were obtained from the SEER database. This database has information on the different 
histological types of prostate cancer. After a thorough data organization, a total of 23,998 
cases of adenocarcinoma histology type were available for analysis. This number 
represents reported cases from 1988 to 2003. Disease characteristics such as age of the 
patient, geographic region of the reported case, stage of the cancer, tumor grade, survival 
time, and treatment type among others were reported for each patient. 
Treatment is categorized as radiation therapy, surgery, combination of radiation and 
surgery, and no treatment. The stage of the prostate cancer and the grade of the tumor are 
categorized as stage I, stage II, stage III, stage IV and grade I (well differentiated), grade 
II (moderately differentiated), grade III (poorly differentiated), and grade IV 
(undifferentiated), respectively. The 23,998 records originated from four geographic 
regions as follows: Northeast (Connecticut), South (Metropolitan Atlanta), Midwest 
(Iowa and Metropolitan Detroit), and West (San Francisco-Oakland, Hawaii, New 
Mexico, Seattle-Puget Sound, and Utah). The survival times are measured in years and all 
recorded deaths are due to prostate cancer. 
4.2.1 Overall Stage Distribution by Race, Treatment, Region, Age, and Tumor Grade 
The overall distribution of the stage of prostate cancer diagnosis by race, type of 
treatment, region of disease classification, tumor grade, and age of the patient are given 
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in Table 4.1. Overall, 38% of the cases were classified in stage I, 27.5% in stage II, 26% 
in stage III, and 8.5% in stage IV. The pattern of prostate cancer disease varies by race, 
treatment, region of classification, age of patient, and tumor grade. Approximately 91.5% 
of all the cases were White American patients and 8.5% were African American patients. 
Nearly half (41.9%) of the African American patients were classified in stage I.  
Table 4.1: Overall distribution of stage of cancer by race, treatment, region, age, and 
tumor grade 
  Stage I Stage II Stage III Stage IV 
   n % n % n % n % Total 
Overall 9121 38.0 6600 27.5 6229 26.0 2048 8.5 23998 
Race 
              White 8265 37.7 6083 27.7 5798 26.4 1809 8.2 21955 
     African American 856 41.9 517 25.3 431 21.1 239 11.7 2043 
Treatment 
              Radiation 2231 55.1 1238 30.6 434 10.7 147 3.6 4050 
     Surgery 5166 32.2 4536 28.3 5023 31.4 1297 8.1 16022 
     Radiation & Surgery 520 27.4 432 22.8 635 33.4 311 16.4 1898 
     No Treatment 1204 59.4 394 19.4 137 6.8 293 14.4 2028 
Region          
     Northeast  1343 60.3 422 19.0 329 14.8 131 5.9 2225 
     South  350 27.5 344 27.1 485 38.2 91 7.2 1270 
     Midwest  3479 39.2 2419 27.2 2197 24.7 794 8.9 8889 
     West  3949 34.0 3415 29.4 3218 27.7 1032 8.9 11614 
Age (years)                   
     40-49 132 27.9 142 30.0 148 31.3 51 10.8 473 
     50-59 1109 28.8 1155 29.9 1236 32.0 358 9.3 3858 
     60-69 3056 31.6 2705 27.9 3059 31.6 865 8.9 9685 
     70-79 3690 45.6 2122 26.3 1660 20.5 616 7.6 8088 
     80+ 1134 59.9 476 25.1 126 6.7 158 8.3 1894 
Tumor Grade          
     I 0 0 1050 69.1 372 24.5 98 6.4 1520 
     II 8085 45.4 4588 25.7 4137 23.2 1021 5.7 17831 
     III 1014 23.5 840 19.4 1613 37.3 856 19.8 4323 
     IV 22 24.7 18 20.2 37 41.6 12 13.5 89 
     Unknown 0 0 104 44.2 70 29.8 61 26.0 235 
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Variation in treatment patterns show that of all the patients, 66.8% had surgery, 16.9% 
had radiation therapy, 8.4% had no form of cancer related treatment, and 7.9% had 
combination of surgery and radiation therapy. More than half of the patients reported to 
have received radiation therapy (55.1%) or no form of treatment (59.4%) were classified 
in stage I. Surgery was more typical among patients classified in stage I (32.2%), stage II 
28.3%, or stage III (31.4%). Patients undergoing combination of surgery and radiation 
therapy compared with the other types of treatment show a higher proportion in stage III 
(33.4% vs. 31.4%, 10.7%, and 6.8%) and stage IV (16.4% vs. 14.4%, 8.1%, and 3.6%). 
Of all the patients, nearly half of the reported cases (48.4%) were from West region, 37% 
were from Midwest region, 9.3% were from Northeast region, and 5.3% were from South 
region. Of all the cases from Northeast region, 60.3% were classified in stage I. With the 
exception of cases classified in this category, the distribution of the stage of disease was 
relatively uniform across the other regions. 
The distribution of the disease by age show that 40.3% of the patients were in their 60s, 
33.7% were in their 70s, 16.1% were in their 50s, 7.9% were 80+ years, and 2% were in 
their 40s. The distribution of stage of disease was relatively uniform across age group 
except in stage I and stage III. More than half of the 80+ years patients (59.9%) were 
classified in stage I and 6.7% were classified in stage III. Also, nearly half of the patients 
in their 70s (45.6%) were also classified in stage I. 
Overall, more than half (74.3%) of the tumors were moderately differentiated, 18% 
poorly differentiated, 6.3% well differentiated, 1% unknown, and less than 1% (0.4%) 
undifferentiated. The stage distribution of tumor grade was fairly uniform except for well 
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differentiated tumors in stage I (0%), stage II (69.1%), or stage IV (6.4%); moderately 
differentiated tumors in stage I (45.4%) or stage IV (5.7%); undifferentiated tumors in 
stage III (41.6%); and non-classified tumor grades in stage I (0%) or stage II (44.2%). 
4.2.2 Stage Distribution by Treatment, Region, Age, and Tumor Grade for White 
Americans 
The distribution of the stage of the cancer as a function of treatment type, region of 
disease classification, tumor grade and age of the patient for White American patients are 
given in Table 4.2. 
Of all the White American patients, 37.7% of the cases were classified in stage I, 27.7% 
in stage II, 26.4% in stage III, and 8.2% in stage IV. Variation in treatment patterns show 
that of all the patients, 67.7% had surgery, 16.6% received radiation therapy, 8.0% had no 
form of treatment, and 7.7% had combination of surgery and radiation therapy. For 
patients who received radiation therapy or no treatment, more than half were classified in 
stage I (55.3% & 61.2%, respectively). Surgery was more typical among patients 
classified in stage I (31.9%), stage II (28.5%), or stage III (31.8%). Patients with 
combination of surgery and radiation therapy treatment were comparatively higher in 
stage IV (17.2% vs. 13.3%, 7.8%, & 3.5%). 
In regards to regional classification, more than half of the reported cases (51.0%) were 
from West region, 34.9% from Midwest region, 9.5% from Northeast region, and 4.6% 
from South region. Of all the cases from the Northeast region, 60.2% were classified in 
stage I. The distribution of the disease by age show that 40.3% of the patients were in 
their 60s, 34.0% were in their 70s, 15.9% were in their 50s, 8.0% were 80+ years, and 
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1.8% were in their 40s. More than half of the patients aged 80+ years (60.3%) were 
classified in stage I and nearly half of the patients in their 70s (45.0%) were also 
classified in stage I.  
Table 4.2: Distribution of stage of cancer by treatment, region, age, and tumor grade for 
White Americans 
  Stage I Stage II Stage III Stage IV 
   n % n % n % n % Total 
Overall 8265 37.7 6083 27.7 5798 26.4 1809 8.2 21955 
Treatment 
              Radiation 2018 55.3 1120 30.7 384 10.5 126 3.5 3648 
     Surgery 4736 31.9 4238 28.5 4723 31.8 1159 7.8 14856 
     Radiation & Surgery 440 25.8 385 22.6 585 34.4 292 17.2 1702 
     No Treatment 1071 61.2 340 19.4 106 6.1 232 13.3 1749 
Region          
     Northeast  1260 60.2 407 19.5 302 14.4 123 5.9 2092 
     South  259 25.6 274 27.0 420 41.5 60 5.9 1013 
     Midwest  2931 38.2 2111 27.5 1966 25.7 659 8.6 7667 
     West  3815 34.1 3291 29.4 3110 27.8 967 8.7 11183 
Age (years)                   
     40-49 115 28.6 117 29.1 128 31.8 42 10.5 402 
     50-59 993 28.5 1052 30.1 1134 32.5 310 8.9 3489 
     60-69 2741 31.0 2487 28.1 2845 32.1 776 8.8 8849 
     70-79 3363 45.0 1984 26.6 1578 21.1 545 7.3 7470 
     80+ 1053 60.3 443 25.4 113 6.5 136 7.8 1745 
Tumor Grade          
     I 0 0 971 69.9 342 24.6 77 5.5 1390 
     II 7349 44.8 4241 25.9 3890 23.7 922 5.6 16402 
     III 898 23.1 760 19.6 1469 37.8 756 19.5 3883 
     IV 18 22.2 17 21.0 35 43.2 11 13.6 81 
     Unknown 0 0 94 47.2 62 31.2 43 21.6 199 
 
The distribution of the tumor grades reveal that approximately 74.7% of the tumors were 
moderately differentiated, 17.7% were poorly differentiated, 6.3% were well 
differentiated, 0.4% were undifferentiated and 0.9% were unknown. More than half of the 
well differentiated tumors were classified in stage II and nearly half of the unknown 
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tumor grades were also classified in stage II. Among the moderately differentiated 
tumors, approximately 44.8% were from stage I. 
4.2.3 Stage Distribution by Treatment, Region, Age, and Tumor Grade for African 
Americans 
The distribution of stage of the cancer by the types of treatment, region of cancer 
classification, grade of the tumor, and age of the patient for African Americans are given 
in Table 4.3. 
Of all the African American patients, approximately 41.9% of the cases were classified in 
stage I, 25.3% in stage II, 21.1% in stage III, and 11.7% in stage IV. Variation in 
treatment patterns show that of all the patients, 56.1% had surgery, 20.3% received 
radiation therapy, 13.4% had no form of cancer treatment, and 10.2% had combination of 
surgery and radiation therapy. More than half of the patients who received radiation 
therapy were classified in stage I (51.4%) and nearly half of the patients who did not 
receive any form of cancer related treatment were also classified in stage I (48.4%). 
Furthermore, patients who did not receive any form of treatment were comparatively 
higher in stage IV (20.7% vs. 14.9%, 10.3%, & 8.0%). Surgery or combination of surgery 
and radiation therapy treatments were more typical among patients classified in stages I, 
II, and III. 
Regional differences show that, more than half of the reported cases (59.8%) originated 
from Midwest region, 21.1% from West region, 12.6% from South region, and 6.5% 
from Northeast region. Of all the cases from the Northeast region, 62.4% were classified 
in stage I and nearly half of the cases from Midwest region were also classified in stage I 
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(44.8%). The distribution of the disease by age show that 40.9% of the patients were in 
their 60s, 30.2% were in their 70s, 18.1% were in their 50s, 7.3% were 80+ years, and 
3.5% were in their 40s. More than half of the patients in their 70s (52.9%) or age 80+ 
years (54.4%) were classified in stage I. Furthermore, patients age 80+ years were 
comparatively higher in stage IV (14.8% vs. 13.5%, 12.7%, 11.5%, & 10.6%). 
Table 4.3: Distribution of stage of cancer by treatment, region, age, and tumor grade for 
African Americans 
  Stage I Stage II Stage III Stage IV 
   n % n % n % n % Total 
Overall 856 41.9 517 25.3 431 21.1 239 11.7 2043 
Treatment 
              Radiation 213 51.4 118 28.5 50 12.1 33 8.0 414 
     Surgery 430 37.5 298 26.0 300 26.2 118 10.3 1146 
     Radiation & Surgery 80 38.5 47 22.6 50 24.0 31 14.9 208 
     No Treatment 133 48.4 54 19.6 31 11.3 57 20.7 275 
Region          
     Northeast  83 62.4 15 11.3 27 20.3 8 6.0 133 
     South  91 35.4 70 27.2 65 25.3 31 12.1 257 
     Midwest  548 44.8 308 25.2 231 18.9 135 11.1 1222 
     West  134 31.1 124 28.8 108 25.0 65 15.1 431 
Age (years)                   
     40-49 17 23.9 25 35.2 20 28.2 9 12.7 71 
     50-59 116 31.4 103 27.9 102 27.7 48 13.0 369 
     60-69 315 37.7 218 26.1 214 25.6 89 10.6 836 
     70-79 327 52.9 138 22.3 82 13.3 71 11.5 618 
     80+ 81 54.4 33 22.1 13 8.7 22 14.8 149 
Tumor Grade          
     I 0 0 79 60.8 30 23.1 21 16.1 130 
     II 736 51.5 347 24.3 247 17.3 99 6.9 1429 
     III 116 26.4 80 18.2 144 32.7 100 22.7 440 
     IV 4 50.0 1 12.5 2 25.0 1 12.5 8 
     Unknown 0 0 10 27.8 8 22.2 18 50.0 36 
 
The tumor grade distribution reveal that more than half of the tumors (69.9%) were 
moderately differentiated, 21.5% were poorly differentiated, 6.4% were well 
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differentiated, less than 1% were undifferentiated, and 1.8% were unknown. More than 
half of the well differentiated tumors were classified in stage II, more than half of the 
moderately differentiated tumors were classified in stage I, approximately half of the 
undifferentiated tumors were classified in stage I, and approximately half of the unknown 
tumor grades were classified in stage IV. There is a fairly uniform distribution within the 
poorly differentiated tumors by their stage classification. 
4.2.4 Distribution of Prostate Cancer Treatment by Age of Patient and Region of Cancer 
Classification 
The pattern of treatment by age of the patient and region of cancer classification for 
White and African Americans are given in Table 4.4. 
The data shows variation in treatment selection by age of the patient. Of all the age 
groups, regardless of race, patients were frequently treated by surgery and infrequently by 
combination of surgery and radiation therapy. Furthermore, Older patients age 80+ years 
frequently prefer no cancer related treatment to radiation therapy or combination of 
surgery and radiation therapy (White Americans: 22.3% vs. 15.6% & 3.8% and African 
Americans: 30.2% vs. 8.0% & 5.4%). In addition, the proportion of the older patient’s 
age 80+ years that preferred no treatment was relatively higher among African Americans 
than White Americans. However, both White and African American patients in their 60s 
and 70s frequently received radiation therapy compared to no treatment or combination 
of surgery and radiation therapy. 
In regards to regional classification, patients from both races were frequently treated by 
surgery in all the regions. However, in the northeast region, a reasonable proportion of 
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the patients also received radiation therapy treatment or no cancer related treatment. In 
the south region, a small number of the White American patients had no form of cancer 
treatment while in the Midwest a reasonable number of African American patients 
received radiation therapy treatment. 
Table 4.4: Distribution of prostate cancer treatment by age of patient and region of cancer 
classification 
 
Radiation Surgery 
Radiation & 
Surgery No Treatment 
 
 
n % n % n % n % Total 
White Americans          
Age     40-49 20 5.0 337 83.8 32 8.0 13 3.2 402 
           50-59 236 6.8 2887 82.7 249 7.1 117 3.4 3489 
           60-69 1145 12.9 6581 74.4 713 8.1 410 4.6 8849 
           70-79 1975 26.4 4034 54.0 642 8.6 819 11.0 7470 
           80+ 272 15.6 1017 58.3 66 3.8 390 22.3 1745 
Region          
     Northeast  614 29.4 919 43.9 113 5.4 446 21.3 2092 
     South  86 8.4 812 80.2 97 9.6 18 1.8 1013 
     Midwest  1214 15.8 5258 68.6 653 8.5 542 7.1 7667 
     West  1734 15.5 7867 70.4 839 7.5 743 6.6 11183 
African Americans          
Age     40-49 5 7.1 62 87.3 4 5.6 0 0 71 
           50-59 49 13.3 258 69.9 35 9.5 27 7.3 369 
           60-69 167 20.0 504 60.3 82 9.8 83 9.9 836 
           70-79 169 27.3 258 41.8 67 10.8 124 20.1 618 
           80+ 12 8.0 84 56.4 8 5.4 45 30.2 149 
Region          
     Northeast  32 24.1 66 49.6 11 8.3 24 18.0 133 
     South  25 9.7 181 70.4 19 7.4 32 12.5 257 
     Midwest  267 21.9 647 52.9 136 11.1 172 14.1 1222 
     West  78 18.1 272 63.1 30 7.0 51 11.8 431 
 
4.3 Evaluation of Treatment Types by Stage of Cancer for White Americans 
In this study, we compared the types of treatment using survival and basic parametric 
analysis. Classical distributions were fitted to the observed survival times of the different 
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types of treatment in each stage to identify the probability distribution function that 
characterizes the behavior of the survival times. A P-P and Q-Q plot together with three 
commonly used goodness-of-fit tests; Kolmogorov-Smirnov, Anderson-Darling, and Chi-
Squared were examined to verify the goodness-of-fit. Based on the identified probability 
distribution function, the corresponding maximum likelihood estimates of the parameters 
are obtained together with the analytical structure of the estimated survival function and 
the expected survival time estimated under the appropriate probability distribution 
function. Of all the groups studied, we identified three different probability distribution 
functions; Weibull, Lognormal and Gamma. The theory of estimating their maximum 
likelihood and survival functions have been discussed in chapter 2. 
4.3.1 Stage I  
The appropriate probability distribution function (PDF) that characterize the behavior of 
the survival times in this stage of prostate cancer patients who received radiation therapy 
treatment was three-parameter Weibull probability distribution function with maximum 
likelihood estimates given by shape parameter  ̂        , scale parameter  ̂       , 
and location parameter  ̂         . The actual form of the probability density function 
as given in chapter 2 is of the form, 
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By way of illustration, fitted graphical display of the identified Weibull density function 
with the inherent maximum likelihood estimates and corresponding P-P plot are given by 
Figure 4.1. The P-P plot follows a reasonable straight line pattern indicating that 3P-
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Weibull density function is a good fit for the observed survival times. This was consistent 
with the results of the three formal goodness-of-fit tests. 
 
Figure 4.1: Fitted 3P-Weibull probability density function and P-P plot 
Recall from chapter 2, the analytical form for estimating expected value and the survival 
function under Weibull probability distribution are given by, 
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respectively. From the parameter estimates, the estimated survival function is given by, 
 ̂       [ (
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and the expected survival time is estimated as follows: 
                    (  
 
      
)              .  
Following the process above, we have identified the probability distribution functions 
that characterize the behavior of the survival times under treatment options surgery, 
combination of surgery and radiation, and no form of cancer treatment. Three-parameter 
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Weibull was again identified for surgery treatment, two-parameter Weibull for 
combination of surgery and radiation therapy, and three-parameter lognormal for no 
treatment. Their corresponding maximum likelihood estimates (MLE), expected survival 
times, and estimated survival functions are given in Table 4.5. 
The expected survival time for patients receiving combination of surgery and radiation 
therapy treatment is approximately 8.6 years with a 44.3% chance of survival, radiation 
therapy is 7.9 years with a likelihood of 46.3%, surgery is 7.0 years with a likelihood of 
41.7%, and no treatment is 6.2 years with a likelihood of 42.7%. The variation in the 
expected survival times is partly due to differences in the level of survivorship. A 
graphical display of the estimated survival functions is given by Figure 4.2. 
Table 4.5: PDFs of the survival times of stage I White American patients by treatment, 
MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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Figure 4.2: Survival function for stage I White American patients by treatment 
Visually, there are differences in the survivorships. Based on this knowledge, pair-wise 
comparison tests of the survivorships were performed to establish all possible differences 
and the results given in Table 4.6. From the table, all the p-values indicate differences 
between the survivorships. Thus, combination of surgery and radiation therapy shows a 
better survivorship than surgery, radiation therapy, or no treatment. Radiation therapy on 
average shows a better survivorship than surgery or no treatment, and surgery also shows 
a better survivorship than no treatment. However, between radiation therapy and surgery, 
radiation therapy shows a better survivorship than surgery within 13 years and after 13 
years, surgery tends to show a better survivorship than radiation therapy. These 
differences in survivorships in conjunction with the expected survival times reveal that 
combination of surgery and radiation was more effective followed by radiation therapy, 
surgery, and no form of cancer treatment. 
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Table 4.6: Pair-wise comparison of stage I prostate cancer survivorship by treatment for 
White Americans 
                                       
                              
                                   
                                   
                                    
                                    
                                       
                                      
                                      
 
4.3.2 Stage II  
In this stage, the Weibull distribution was identified as the appropriate probability 
distribution function that characterizes the behavior of the survival times under the 
different types of treatment. More specifically, the three-parameter Weibull was 
identified for radiation therapy, surgery, and no treatment whereas two-parameter 
Weibull was appropriate for combination of surgery and radiation therapy. Details of the 
identified probability distribution functions, maximum likelihood estimates, expected 
survival times, and estimated survival functions are given in Table 4.7. 
The approximate expected survival time for combination of surgery and radiation therapy 
treatment is 9.0 years with 46.0% likelihood to survive this number of years, surgery is 
8.2 years with a likelihood of 44.9%, radiation therapy is 7.9 years with a likelihood of 
45.4%, and no treatment is 5.8 years with a likelihood of 43.5%. Graphs of the estimated 
survival functions as a function of time are given by Figure 4.3. 
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Table 4.7: PDFs of the survival times of stage II White American patients by treatment, 
MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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Figure 4.3: Survival function for stage II White American patients by treatment 
A visual inspection of the survival curves suggests differences in the survivorships. Thus, 
a formal statistical test was performed to establish all possible differences and the results 
given in Table 4.8. The test results indicate that on average combination of surgery and 
20151050
1.0
0.8
0.6
0.4
0.2
0.0
Time (years)
S
 (
t)
No Treatment
Radiation Therapy
Surgery
Radiation & Surgery
Variable
Stage II Survival Function by Treatment for White Men
 70 
 
radiation shows a better survivorship than surgery, radiation therapy, or no treatment. 
Furthermore, surgery on average shows a better survivorship than radiation therapy or no 
treatment, and radiation therapy shows a better survivorship than no treatment. However, 
it is important to mention that combination of surgery and radiation therapy showed a 
better survivorship than surgery within 14 years. After 14 years, surgery began to show a 
better survivorship than combination of surgery and radiation. Also, surgery showed a 
better survivorship than radiation therapy after 6 years, but within 6 years, radiation 
therapy showed a better survivorship than surgery. Based on the observed differences in 
survivorship and taking into account the expected survival times, combination of surgery 
and radiation therapy was more effective in this stage followed by radiation therapy, 
surgery, and no form of cancer treatment.  
Table 4.8: Pair-wise comparison of stage II prostate cancer survivorship by treatment for 
White Americans 
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4.3.3 Stage III  
The Weibull distribution was again identified as the appropriate probability distribution 
function that characterizes the behavior of the survival times under the different types of 
treatment. More specifically, the three-parameter Weibull was identified for surgery and 
combination of radiation therapy and surgery, whereas two-parameter Weibull was 
appropriate for radiation therapy and no treatment. Table 4.9 shows the identified 
probability distribution functions, maximum likelihood estimates, expected survival 
times, and estimated survival functions. 
Table 4.9: PDFs of the survival times of stage III White American patients by treatment, 
MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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The expected survival time for surgery treatment is approximately 9.2 years with 49.5% 
chance of surviving this number of years, combination of surgery and radiation is 
approximately 9.1 years with a likelihood of 47.1%, radiation therapy is approximately 
7.4 years with a likelihood of 43.3%, and no treatment is approximately 5.5 years with a 
likelihood of 40.3%. A graphical display of the estimated survival functions is given by 
Figure 4.4.  
 72 
 
 
Figure 4.4: Survival function for stage III White American patients by treatment 
The graphs reveal possible differences between the survivorships and this observation 
was supported by a statistical test. The results of the tests are given in Table 4.10. From 
the test results, surgery on average shows a better survivorship than combination of 
radiation and surgery, radiation therapy, or no treatment. Combination of surgery and 
radiation on average also shows a better survivorship than radiation therapy or no 
treatment, and radiation therapy shows a better survivorship than no treatment. However, 
a detailed test revealed that surgery shows a better survivorship than combination of 
surgery and radiation after 5 years. Also, surgery shows a better survivorship than 
radiation therapy within 17 years. Combination of surgery and radiation shows a better 
survivorship than radiation therapy within 16 years. The differences in survivorships 
together with the expected survival times suggest surgery was more effective in this stage 
followed by combination of radiation therapy and surgery, radiation therapy, and no 
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treatment. In this ranking process, there was a trade-off between the level of survivorship 
and the expected survival time.  
Table 4.10: Pair-wise comparison of stage III prostate cancer survivorship by treatment 
for White Americans 
                                       
                                
                                   
                                   
                                   
                                    
                                       
                                      
                                     
                                         
                                        
                                      
                                        
 
4.3.4 Stage IV  
Here, the Gamma and Weibull distributions were identified to characterize the behavior 
of the survival times under the different types of treatment. The three-parameter gamma 
probability distribution was identified for radiation therapy, two-parameter Weibull for 
combination of radiation and surgery, and three-parameter Weibull for both surgery and 
no treatment. The estimated maximum likelihoods, expected survival times, and 
estimated survival functions are given in Table 4.11. 
The expected survival time for combination of surgery and radiation therapy treatment is 
approximately 7.1 years with a survival probability of 40.9%, surgery is 6.4 years with a 
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likelihood of 41.0%, radiation therapy is 5.8 years with a likelihood of 38.6%, and no 
treatment is 4.2 years with a likelihood of 35.5%. A graphical display of the estimated 
survival functions as a function of time is given by Figure 4.5. 
Table 4.11: PDFs of the survival times of stage IV White American patients by treatment, 
MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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There are differences in the survivorships and thus, we proceeded to perform a pair-wise 
comparison test to establish all possible differences. All the test results in Table 4.12 are 
statistically significant at the 5% level. This indicates that undergoing combination of 
surgery and radiation therapy shows a better survivorship than surgery, radiation therapy, 
or no treatment. Furthermore, surgery showed a better survivorship than radiation therapy 
or no treatment, and radiation therapy also showed a better survivorship than no 
treatment. Based on the observed differences in survivorship and accounting for the 
expected survival times, combination of surgery and radiation therapy was a more 
effective form of treatment in this stage followed by surgery, radiation therapy, and no 
cancer related treatment.  
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Figure 4.5: Survival function for stage IV White American patients by treatment 
Table 4.12: Pair-wise comparison of stage IV prostate cancer survivorship by treatment 
for White Americans 
                                       
                                
                                   
                                   
                                    
                                    
                                       
 
4.4 Evaluation of Treatment Types by Stage of Cancer for African Americans 
Using the same concept from section 4.3, different classical distributions were fitted to 
the observed survival times in each stage of the prostate cancer under the different types 
of treatment. The fit of the distributions were examined through P-P plot, Q-Q plot, and 
the three commonly used goodness-of-fit tests. Four probability distribution functions, 
namely, Weibull, Lognormal, Gumbel Maximum, and Gamma were identified for the 
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various groups studied. The theory of estimating their maximum likelihood and survival 
functions have been discussed in chapter 2. 
4.4.1 Stage I 
In this stage, we identified the three-parameter Weibull probability distribution function 
as the appropriate distribution that characterize the behavior of the survival times for 
radiation therapy, surgery, and combination of radiation and surgery. The three-parameter 
lognormal distribution was identified to characterize the survival times of patients with 
no form of cancer related treatment. Maximum likelihood estimates of the identified 
probability distributions, expected survival times, and estimated survival functions are 
given in Table 4.13. 
By way of illustration, let’s consider the survival times of African Americans who did not 
undergo any form of cancer related treatment with underlying lognormal probability 
density function with inherent maximum likelihood estimates given by shape parameter 
 ̂        , scale parameter  ̂        , and location parameter  ̂         . The 
actual form of the probability density function as given in chapter 2 is of the form, 
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. 
Fitted graphical display of the identified lognormal density function with the inherent 
parameter estimates and corresponding P-P plot are given by Figure 4.6. The P-P plot 
follows a reasonable straight line pattern indicating that 3P-lognormal density function is 
a good fit for the observed survival times. This was consistent with the three formal 
goodness-of-fit tests. 
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Figure 4.6: Fitted 3P-lognormal probability density function and P-P plot 
Recall from chapter 2, the analytical form for estimating expected value and survival 
function under lognormal probability distribution are given by, 
      ̂     ( ̂  
 ̂ 
 
)  and          [
      ̂   ̂
 ̂
], 
respectively. From the parameter estimates, the estimated survival function is given by, 
 ̂       [
  (           )       
      
], 
and the expected survival time is estimated as follows: 
                (       
       
 
)              .  
Following the process described above, we have identified the probability distribution 
functions that characterize the behavior of the survival times under treatment options 
combination of surgery and radiation, surgery, and radiation therapy and obtained their 
corresponding estimates as given in Table 4.13. 
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Table 4.13: PDFs of the survival times of stage I African American patients by treatment, 
MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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 ̂          
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Figure 4.7: Survival function for stage I African American patients by treatment 
The expected survival time for patients receiving combination of surgery and radiation 
therapy treatment is approximately 8.1 years with 44.9% chance of survival this period of 
time, radiation therapy is 7.3 years with a likelihood of 46.3%, surgery is 6.9 years with a 
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likelihood of 43.0%, and no treatment is 5.4 years with a likelihood of 39.9%. Graphs of 
the estimated survival functions are given by Figure 4.7. Visually, the graphs reveal 
differences in the survivorships. Thus, we proceed to perform a pair-wise comparison test 
of the survivorships to establish all possible differences. Details of the tests results are 
given in Table 4.14.  
Table 4.14: Pair-wise comparison of stage I prostate cancer survivorship by treatment for 
African Americans 
                                       
                               
                                   
                                   
                                    
                                    
                                       
                                      
                                   
                                          
                                        
 
All the tests are statistically significant at the 5% level indicating that on average 
combination of radiation and surgery treatment shows a better survivorship than surgery, 
radiation therapy, or no treatment. Radiation therapy on average shows a better 
survivorship than surgery or no treatment, and surgery also shows a better survivorship 
than no treatment. However, between surgery and combination of surgery and radiation 
therapy, combination of surgery and radiation therapy shows a better survivorship than 
surgery within 15 years and the effect changes in favor of surgery after 15 years. Also, 
between radiation therapy and surgery, radiation therapy shows a better survivorship than 
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surgery within 10 years and the effect changes after 10 years. Now, based on the 
expected survival times and taking into account the changes in survivorship, it is evident 
that combination of surgery and radiation therapy was more effective in this stage 
followed by radiation therapy, surgery, and no form of cancer related treatment. 
4.4.2 Stage II  
Two distributions, namely, Weibull and Gumbel Maximum were identified in this stage. 
Specifically, two-parameter Weibull was identified for combination of radiation therapy 
and surgery, Gumbel Maximum was identified for no treatment, and three-parameter 
Weibull was identified for radiation therapy as well as surgery. The maximum likelihood 
estimates, expected survival times, and estimated survival functions for these probability 
distributions are given in Table 4.15. 
Table 4.15: PDFs of the survival times of stage II African American patients by 
treatment, MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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The approximate expected survival time for combination of surgery and radiation therapy 
treatment is 8.4 years with 43.1% likelihood to survive this numbers of years, radiation 
therapy is 7.8 years with a likelihood of 45.0%, surgery is 7.1 years with a likelihood of 
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44.4%, and no treatment is 4.2 years with a likelihood of 43.3%. A graphical display of 
the estimated survival functions as a function of time is given by Figure 4.8.  
 
Figure 4.8: Survival function for stage II African American patients by treatment 
The figure reveals differences in survivorship among the types of treatment. Therefore it 
was necessary to perform a pair-wise comparison to evaluate the survivorship between 
the treatment types. Table 4.16 shows the results of the tests. At the 5% level of 
significance, all the pair-wise comparison tests were statistically significant indicating 
that on average, combination of surgery and radiation therapy shows a better survivorship 
than surgery, radiation therapy, or no treatment. Furthermore, radiation therapy shows a 
better survivorship than surgery or no treatment, and surgery shows a better survivorship 
than no treatment. Notice that, combination of radiation therapy and surgery shows a 
better survivorship after 6 years of treatment. However, within 6 years the survivorship 
under radiation therapy treatment is better than combination of surgery and radiation 
therapy. Thus, it is very crucial to consider the changes in survivorship while accounting 
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for the expected survival times. In this regard, radiation therapy would be considered the 
more effective form of treatment in this stage followed by combination of surgery and 
radiation therapy, surgery, and no form of cancer treatment. 
Table 4.16: Pair-wise comparison of stage II prostate cancer survivorship by treatment 
for African Americans 
                                       
                                
                                 
                                   
                                    
                                    
                                       
                                      
                                       
 
4.4.3 Stage III  
Here, we identified three distributions namely Weibull, Gamma, and Gumbel Maximum. 
The probability distribution function that characterizes the behavior of the survival times 
for combination of radiation and surgery was Gumbel Maximum, no treatment was three-
parameter Weibull, radiation therapy was three-parameter Gamma and surgery was also 
three-parameter Gamma. The maximum likelihood estimates of these probability 
distributions, expected survival times, and estimated survival functions are given in Table 
4.17. 
The approximate expected survival time for combination of surgery and radiation therapy 
treatment is 10.3 years with 43.1% chance of surviving this number of years, surgery is 
8.3 years with a likelihood of 48.2%, radiation therapy is 8.2 years with a likelihood of 
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44.2%, and no treatment is 6.6 years with a likelihood of 40.7%. Plots of the estimated 
survival functions as a function of time are given by Figure 4.9.  
Table 4.17: PDFs of the survival times of stage III African American patients by 
treatment, MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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The plot shows some level of variations in survivorship among the treatment types. These 
observed variations were supported by a pair-wise comparison test and the results given 
in Table 4.18. All the tests except one were statistically significant at the 5% level 
indicating that on average, combination of radiation therapy and surgery shows a better 
survivorship than surgery, radiation therapy, or no treatment. Furthermore, surgery on 
average shows a better survivorship than radiation therapy or no treatment, and radiation 
therapy also shows a better survivorship than no treatment. However, a detailed test 
performed between the two treatments, surgery and radiation therapy revealed that within 
the first 3 years, radiation therapy shows a better survivorship than surgery; and between 
3 to 13 years, surgery shows a better survivorship than radiation therapy; but no statistical 
difference was observed between the two treatments after 13 years. These observed 
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changes in survivorship in conjunction with the expected survival times give a reflection 
that combination of surgery and radiation therapy treatment was more effective in this 
stage followed by surgery, radiation therapy, and no treatment. 
 
Figure 4.9: Survival function for stage III African American patients by treatment 
Table 4.18: Pair-wise comparison of stage III prostate cancer survivorship by treatment 
for African Americans 
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4.4.4 Stage IV  
Here we identified three probability distribution functions that characterize the behavior 
of the survival times under the different types of treatment. They are Weibull, Gamma, 
and Lognormal probability distributions. We identified two-parameter Weibull for 
radiation therapy, three-parameter lognormal for combination of surgery and radiation 
therapy, three-parameter gamma for surgery and no treatment. The maximum likelihood 
estimates, expected survival times, and estimated survival functions for the identified 
probability distribution functions are given in Table 4.19. 
The expected survival time for combination of surgery and radiation therapy treatment is 
approximately 7.0 years with 48.7% chance of survival, surgery is approximately 6.0 
years with 36.5% chance of survival, no cancer related treatment is approximately 4.8 
years with 34.9% chance of survival, and radiation therapy is approximately 1.7 years 
with 36.3% chance of survival. A graphical display of the estimated survival functions is 
given by Figure 4.10.  
Table 4.19: PDFs of the survival times of stage IV African American patients by 
treatment, MLEs, expected survival times, and estimated survival functions 
Treatment PDF MLE 
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Figure 4.10: Survival function for stage IV African American patients by treatment 
Visually, the graphs reveal differences in the level of survivorships. Thus, we proceed to 
perform a pair-wise comparison test to establish all the possible differences. Results of 
the tests are given in Table 4.20. 
All the tests except one were statistically significant at the 5% level indicating that on 
average, combination of radiation therapy and surgery shows a better survivorship than 
surgery, radiation therapy, or no treatment. Surgery also shows a better survivorship than 
radiation therapy or no treatment, and no cancer related treatment also shows a better 
survivorship than radiation therapy. However, between surgery and combination of 
surgery and radiation therapy treatments, we observed that combination of surgery and 
radiation therapy shows a better survivorship within 10 years. After 10 years no statistical 
difference was observed between the two treatments.  
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Based on this observed change in survivorship and taking into account the expected 
survival times, it is evident that combination of surgery and radiation therapy was more 
effective in this stage followed by surgery, no form of cancer related treatment, and 
radiation therapy. 
Table 4.20: Pair-wise comparison of stage IV prostate cancer survivorship by treatment 
for African Americans 
                                       
                                
                                   
                                   
                                  
                                    
                                       
                                         
                                         
 
4.5 Comparison of the Treatments by Stage for White and African Americans 
The comparison of the effectiveness of each treatment option as a function of stage and 
race is based on the calculated expected value of the corresponding identified probability 
distribution function. That is, for stage III prostate cancer patients, the expected survival 
time for White and African Americans under treatment option combination of surgery 
and radiation therapy are obtained as follows: 
White Americans:       ̂   ̂ (  
 
 ̂
)              (  
 
      
)            . 
African Americans:       ̂         ̂                                  . 
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This means a White American that is identified in this stage and undergoes combination 
of surgery and radiation therapy treatment has a life expectancy of approximately 9.1 
years whereas an African American identified in the same stage and undergoes similar 
treatment has a life expectancy of approximately 10.3 years. Table 4.21 gives such 
comparison for all stages and all treatments as a function of race. 
From Table 4.21, we can conclude the following. 
 For stage I, the treatment option that maximizes the life expectancy for both 
White and African Americans is combination of surgery and radiation therapy. 
However, there is a six month improvement in White Americans over African 
Americans. Also, White Americans going through just radiation therapy treatment 
or no cancer related treatment has seven months and nine months improvement, 
respectively over African Americans. The response for just surgery treatment is 
approximately the same for both races. 
 Combination of surgery and radiation therapy treatment for both White and 
African Americans identified in stage I will increase their life expectancy by more 
than two years over not doing anything. 
 In stage II, the treatment option that maximizes the life expectancy for White and 
African Americans is combination of surgery and radiation therapy. However, 
there is a seven month improvement in White Americans over African Americans. 
In addition, White men going through just surgery or decide not to do anything 
will have a one year improvement in life expectancy over African American men 
in both cases. 
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 The life expectancy for White and African Americans identified in stage II going 
through just radiation therapy treatment is approximately the same. But there is an 
increase in life expectancy for more than seven months for both races going 
through combination of surgery and radiation therapy over just radiation therapy. 
 For stage III, the treatment option that maximizes the life expectancy for White 
men is surgery with a ten month improvement over Africa American men. On the 
other hand, the treatment option that maximizes the life expectancy of African 
American men is combination of surgery and radiation therapy with a one year 
improvement over White men. 
 African American men identified in stage III going through just radiation therapy 
or no cancer related treatment will increase their life expectancy by one year over 
White American men under similar treatment. The response for African 
Americans going through just surgery or radiation therapy treatment is 
approximately the same. 
 In stage IV, the treatment option that maximizes the life expectancy for both 
White and African American men is combination of surgery and radiation therapy 
with approximately the same response.  
 The response in life expectancy for African Americans identified in stage IV for 
going through just radiation therapy over not doing anything will decrease their 
improvement by three years. On the other hand, going through combination of 
surgery and radiation therapy or just surgery will improve their life expectancy 
over not doing anything. Thus, African Americans are better off not doing 
anything rather than going through radiation therapy in this stage. 
 90 
 
Table 4.21: Comparison of treatment by stage as a function of race 
 Stage I Stage II Stage III Stage IV 
Treatment White A.A. White A.A White AA White AA 
No treatment 6.1970 5.4045 5.8047 4.2210 5.5044 6.5820 4.1501 4.7923 
Radiation therapy 7.9118 7.3470 7.8765 7.8408 7.4192 8.2027 5.8196 1.6786 
Surgery 6.9609 6.9279 8.2011 7.1411 9.2473 8.2918 6.3963 6.0193 
Radiation + Surgery 8.5520 8.0513 8.9687 8.4040 9.0707 10.3100 7.1062 6.9667 
 
4.6 Conclusion 
The relationship of prostate cancer survival with treatment has been identified for some 
time. This study reinforces the idea taking into account the association of other 
prognostic factors. The study has shown that prostate cancer treatment varies by stage of 
the cancer, geographic region of the reported case, the tumor grade of the cancer, race 
and age of the patient. 
Overall, the race and age of the patient, the geographic region of the reported case, and 
the grade of the tumor were independently associated with treatment in each classified 
stage of the prostate cancer. With the exception of race, similar association was observed 
among White American patients. However, among the African American men, the age of 
the patient and the geographic region of the reported case were not statistically associated 
with treatment for patients classified in stage IV. Furthermore, there was no statistical 
association between tumor grade and treatment for stage I patients. African American 
patients’ age less than 50 years as well as patient’s age 80+ years showed no association 
between treatment and the stage of the cancer. Also cases reported from the Northeast 
region revealed no association between treatment and stage of the cancer. There was no 
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association between stage of the cancer and the type of treatment for tumors that were 
well differentiated, undifferentiated, or unclassified (unknown). 
Evidence from the analysis have shown that regardless of the stage of the prostate cancer, 
White American patients are expected to have less survival time if no form of cancer 
related treatment is administered. A similar result was observed among African American 
patients except for those classified in stage IV. In stage IV, African American patients 
treated with only radiation therapy are expected to have less survival time compared to 
those who had only surgery, combination of surgery and radiation therapy, or no cancer 
related treatment. 
There were variations in the efficacy of the treatment types considered in this study. The 
evaluation process was solely based on the observed changes in survivorship and the 
estimated expected survival times. For White American patients, combination of surgery 
and radiation therapy treatment was ranked 1 in stage I, II, & IV, and 2 in stage III. 
Surgery treatment was ranked 1 in stage III, 2 in stage IV, and 3 in stage I & II. Radiation 
therapy treatment was ranked 2 in stage I & II, and 3 in stage III & IV. No cancer related 
treatment was ranked 4 in all the four stages. For African American patients, combination 
of surgery and radiation therapy treatment was ranked 1 in stage I, III, & IV, and 2 in 
stage II. Surgery treatment was ranked 2 in stage III & IV, and 3 in stage I & II. 
Radiation therapy treatment was ranked 1 in stage II, 2 in stage I, 3 in stage III, and 4 in 
stage IV. No cancer related treatment was ranked 3 in stage IV, and 4 in stage I, II, & III. 
The use of statistics in the evaluation process has shown that some treatments had better 
survivorship than others for a period of time and later changed its effect or showed no 
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difference. These were evident in stage I, II, & III for White American patients and all 
the four stages for African American patients.  
These findings give useful information to both the patient and the physician in arriving at 
an optimal decision regarding prostate cancer treatment options with some degree of 
assurance. 
4.7 Contributions 
In this chapter we have addressed some important issues concerning prostate cancer 
treatment options surgery, radiation therapy, combination of surgery and radiation 
therapy, and the inclusion of no cancer related treatment. 
 We have identified the probability distribution functions that characterize the 
behavior of the survival times by stage of the cancer and treatment type for White 
Americans and African Americans. 
 For each identified probability distribution and its parameter estimates, we have 
defined the survival function for estimating the survival probabilities and also 
computed the expected survival time. 
 We have statistically evaluated and ranked the effectiveness of the treatment 
options based on the stage the cancer has been classified and race. In addition, 
statistical test has proved that the age of the patient is highly associated with 
treatment and therefore needs to be considered before making an optimal decision 
regarding the treatment of prostate cancer. 
 The findings of this study will go a long way to help both patients and doctors 
make treatment decisions with some degree of assurance and at the same time 
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maintaining cost effective strategies by maximizing survival and minimizing 
treatment cost. 
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Chapter 5: Modeling of Prostate Cancer Mortality 
 
5.1 Introduction 
In today’s global economy, how to describe actual but unknown patterns in mortality has 
been an important task for insurance companies and policy makers. Mortality has shown 
a downward trend over time, but such decline may not be uniform across the age range. It 
is therefore important to accurately measure changes in mortality over time and project 
the correct trend with some confidence. This is of considerable financial importance to 
insurance companies and policy makers. For example, if calculated annuity rates and 
reserves predict higher mortality rates than actually experienced, the policyholders will 
have been undercharged and the insurance company will incur losses and also reserves 
will be understated. 
In this chapter, prostate cancer mortality data for forty-one individual calendar years and 
ten individual age groups for White and African American patients are comprehensively 
modeled using generalized linear modeling techniques. The objective is to develop a 
model which incorporates age, age independent time trend, and age dependent time trend 
adjustment terms. The basic framework can be seen as an extension to the conventional 
parametric graduation techniques used by the Continuous Mortality Investigation (CMI) 
Bureau or can be considered as an extension of the Gompertz-Makeham models [Forfar 
et al., 1988] to include calendar period. This modeling approach has advantages over 
other methods of fitting parametric models in that the other methods represent models for 
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the age variation in mortality and then separately attempt to represent time trends in the 
parameters of these models. 
Renshaw et al. (1996) proposed a modeling structure in the framework of generalized 
linear models which takes into account both the age and trend variations in mortality 
rates. Sithole et al. (2000) adapted Renshaw (1996) modeling structure and applied it to 
data sets pertaining to ultimate experiences and recommended a six-parameter log link 
model. However, in this analysis, the modeling structure suggested by Renshaw (1996) 
would be used to model prostate cancer mortality data for White and African American 
patients. 
5.2 The Data 
Good quality complete data is an integral part for a reliable mortality projection. 
However, it is not easy to obtain data for research. For example, although data on old age 
mortality are collected in most countries of the developed world they are not commonly 
available for the developing countries. Buettuer (2002) claimed that even in the 
developed countries, the quality of age reporting deteriorates among the very old. 
Data was obtained from the SEER program, National Cancer Institute SEER*Stat 
software version 8.0.4. The data comprises of actual number of deaths      with 
corresponding exposures to risk of death      for age group   and calendar year   for 
White and African American patients. Also estimates of the crude mortalities (i.e., the 
ratio of the actual number of deaths to the total number of exposures to risk of death 
multiplied by 100,000) were given for each age group and calendar year. Figure 5.1 
represents a network diagram of the distribution of the data by race and region.  
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Figure 5.1: Schematic diagram of prostate cancer mortality data by race and region 
The data was reported for each five year age group (40-44, 45-49, …, 80-84, 85+ years) 
and we assumed the middle age (42, 47, …, 82, 87 years) as a representative age value in 
the modeling process. Each age group has complete information for calendar years 1969 
to 2009 with one year duration except for age group 40-44 years. The analysis was 
performed for White and African Americans separately for calendar years   = 1969 to 
2009 and middle age   = 42 to 87 years giving a total of 373 observations for African 
Americans and 403 for White Americans. A graphical display of the crude mortality rates 
on the log scale as a function of calendar year   for the overall mortality, and age specific 
mortality for White and African Americans are given by Figures 5.2, 5.3 and 5.4, 
respectively.  
Figure 5.2, shows the pattern of the overall crude mortality for White and African 
Americans. The downward trends indicate that prostate cancer death rates in the United 
States have been decreasing since the early 1990s with some evidence of variation in the 
rates of both White and African Americans. This is consistent with the findings of Jemal 
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et al. (2010). Moreover, Figure 5.3 and 5.4 reveal that this observed trend is more evident 
among patients age 60+ years for both White and African Americans. These trends in 
death rates are reliable measures of progress against prostate cancer since they reflect 
improvements in prevention, early detection, and treatment.  
 
Figure 5.2: Overall log crude mortality rate by race 
 
Figure 5.3: Log crude mortality rate for White American patients 
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Figure 5.4: Log crude mortality rate for African American patients 
5.3 The Proposed Modeling Structure 
Recent changes in mortality challenge mortality projection models and sound projection 
model is crucial. However, the revealed weakness and problems of poor fitting arise 
because most projection models do not capture the dynamics of mortality that is changing 
in a dramatic and fundamental way. 
Here, the modeling structure proposed by Renshaw et al. (1996) would be adapted to 
model changes in mortality for White and African American prostate cancer patients. The 
proposed modeling structure by Renshaw et al. (1996) for modeling the target force of 
mortality     , at age  , in calendar year   is given by the formula, 
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This formula is subject to the convention that some of the     terms may be preset to zero. 
There is a computational advantage when the age and calendar years are both mapped 
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onto the interval [-1, 1]. Thus,    and    are the transformed ages and calendar years 
respectively such that both    and    are mapped onto the interval [-1, 1]. This 
transformation can be achieved by translating the origin to the center of the range and 
then using the semi-range for scaling. That is, 
   
    
  
  and     
    
  
,  
where    
         
 
 and    
         
 
 with equivalent expressions for    and    in 
terms of the maximum and minimum calendar years.     
   denote the Legendre 
polynomials of degree j generated by, 
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where integer    , so that: 
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, … 
are orthogonal with respect to integration on the interval [-1, 1]. Equation (5.1) can be 
rewritten in the form, 
        {∑       
      }   {∑ [   ∑        
      ]  
  
   },   (5.2) 
with the first of the two multiplicative terms equivalent to Gompertz-Makeham 
graduation term            defined as, 
         ∑    
     [∑    
    
   ]
   
   ,  
with the convention that when    , the polynomial term is absent and when    , the 
exponential term is absent [Forfar et al. (1988)]. 
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Note that the first of the two multiplicative terms in equation (5.2) may be interpreted as 
an age adjustment term (or a graduation for age effects), and the second multiplicative 
term may be interpreted as an age dependent trend adjustment term, provided that at least 
one of the     terms is not preset to zero. Also, the first of the second multiplicative term 
may be interpreted as age independent time trend adjustment term. It is important to 
model age dependent time trend effects on mortality and assess their statistical 
significance because it is believed that these effects may exist in some mortality 
experiences. 
The unknown parameters   ,   , and     are estimated by modeling the actual number of 
deaths      as independent realizations of Poisson random variable      of a generalized 
linear model with mean and variance given by, 
 [    ]               ,  and     (    )       ,  
respectively with matching risk exposures     , treated as non-random and   a scale 
parameter measuring the level of dispersion of the Poisson random variable.      is the 
expected number of deaths. 
The generalized linear model can be completed by specifying a link function to the mean 
through the log function, 
   (    )                      ,  
so that 
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where         offsets the general mean    by a known amount conditional on the values 
of   and  . 
The estimation of the unknown parameters is based on the quasi log-likelihood approach 
which involves maximizing the scaled kernel of the log-likelihood expression for the 
independent Poisson random variables     , with expectation,  [    ]      . That is, the 
maximization of the expression, 
 
 
∑ (                 )   .  
The optimal values of   and   can be identified through differences in the adjacent row 
and column model deviance values which is an approximation to the chi-squared 
distribution with one degree of freedom and also checking for the statistical significance 
of the parameter estimates. The model corresponding to the optimum values of   and   is 
refined by introducing the polynomial terms in age and calendar years effects. The 
overall goodness-of-fit of the model is provided through the unscaled deviance value, 
        ∑ {       (
    
 ̂   
)         ̂    }   ,  
where  ̂    is the predicted number of deaths by the model and the corresponding scaled 
deviance is defined as the unscaled deviance divided by the scale parameter  , with   
estimated from dividing the unscaled deviance by the number of degrees of freedom. 
Diagnostic tests are performed on the final model using the unscaled deviance residuals 
defined as the signed values of the square roots of the individual components contributing 
to the value of the unscaled deviance. This is defined by, 
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            ̂    √ {       (
    
 ̂   
)         ̂    }.    (5.3) 
Dividing equation (5.3) by the square root of the scale parameter √  gives the scale 
deviance residuals referred to as the studentized residuals. 
5.4 Modeling and Analysis of Mortality Rate by Race 
5.4.1 Mortality of White Americans 
The data for mortality rates of White Americans was modeled for individual calendar 
years             for individual ages   ranging from 42 to 87+ years. The force of 
mortality      at age  , in calendar year   was modeled using equation (5.1) with the 
transformed age    and transformed calendar year    defined by, 
   
      
    
  and     
      
  
,  
respectively. The transformation rescaled the age and calendar years onto the interval [-1, 
1]. First, we fit the model for the age adjustment term for age effects with the 
multiplicative age independent time trend adjustment term for calendar year effects to 
determine the optimum values of   and  . This was done by monitoring the improvement 
in the model deviance as values of   and   is increased as well as checking for the 
significance of the parameters. Details of the deviance profile are given in Table 5.1. 
Each adjacent increase in row or column deviance is a relative measure of goodness-of-fit 
which is an approximation to the chi-squared distribution with one degree of freedom. 
Here, we settled for     and     because beyond this point, the parameter estimates 
were not statistically significant at the 5% level. Based on this predetermined values of   
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and   the model is refined by introducing the age dependent time trend adjustment terms 
in the sequence of increasing degree of the mixed effect terms. Table 5.2 shows the 
deviance profile for the mixed product terms. 
Table 5.1: Deviance profile for various predictors of degree s and r for White Americans 
 
                        
    1218.2 1080.2 1039.5 1032.9 1019.8 1019.7 
    340.98 203.16 161.63 154.7 141.7 141.59 
    334.33 196.52 154.96 148.02 135.02 134.91 
    333.96 196.15 154.58 147.64 134.64 134.53 
    333.63 195.82 154.25 147.32 134.32 134.21 
    333.61 195.8 154.24 147.3 134.3 134.19 
 
Table 5.2: Deviance profile for additional mixed product terms 
   
Difference 
 
Deviance d.f. Deviance d.f. 
        154.96 396 
  
    90.325 395 64.635 1 
    76.017 394 14.308 1 
    75.086 393 0.931 1 
    53.947 392 21.139 1 
    50.475 391 3.472 1 
    49.861 390 0.614 1 
    47.561 389 2.3 1 
    47.42 388 0.141 1 
    47.144 387 0.276 1 
 
The deviance profile for the mixed effects suggest the possible inclusion of the product 
terms involving the parameters    ,    ,    ,    , and    . However, monitoring the 
statistical significance of the parameter estimates with the inclusion of all possible 
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product terms, we identified that the data was supportive of two different models. The 
analytical structure of the first identified model is given by, 
        [   ∑       
   ∑     
  ∑        
         
 
   
 
   ],   (5.4) 
with corresponding quasi-likelihood parameter estimates given in Table 5.3. The residual 
deviance associated with this model is approximately 75.086 with 393 degrees of 
freedom. The scale parameter         measures the degree of over dispersion present 
and is estimated by dividing the residual deviance by the associated degrees of freedom. 
Table 5.3: Parameter estimates of model (5.4) for White Americans 
Parameter Estimate S.E. t-value 
   2.57376 0.01795 143.385 *** 
   3.61315 0.03753 96.284 *** 
   -1.02535 0.03551 -28.877 *** 
   0.09838 0.01758 5.597 *** 
   -0.18234 0.03104 -5.874 *** 
   -0.46318 0.02487 -18.626 *** 
   -0.20053 0.04719 -4.25 *** 
    0.40522 0.04039 10.032 *** 
    0.2622 0.03208 8.174 *** 
    -0.13333 0.06107 -2.183 * 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
The analytical structure of the second identified model is given by, 
        [   ∑       
   ∑     
  ∑        
                 
        
 
   ], (5.5) 
with corresponding quasi-likelihood parameter estimates given in Table 5.4. The residual 
deviance associated with this second model is approximately 55.152 with 393 degrees of 
freedom. The scale parameter   is approximately 0.140. 
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Table 5.4: Parameter estimates of model (5.5) for White Americans 
Parameter Estimate S.E. t-value 
   2.58649 0.01513 170.898*** 
   3.58579 0.03165 113.308*** 
   -1.00595 0.03001 -33.523*** 
   0.0953 0.0149 6.397*** 
   0.05905 0.02134 2.767** 
   -0.46184 0.02096 -22.032*** 
   -0.294 0.01671 -17.59*** 
    -0.09051 0.03709 -2.44* 
    0.25643 0.02707 9.472*** 
    0.26973 0.02219 12.156*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
By way of assessing and validating the predictive quality of these two models, a 
graphical display of the estimated mortality rates for these models has been superimposed 
onto the crude mortality rates for each age group. Figure 5.5 represents the comparison of 
the two models (5.4 & 5.5) with the crude mortality rates. Visually, both models show 
similar predictive qualities for patient’s age 60+ years. For patients below the age of 60 
years, model (5.5) shows a much better predictive quality than model (5.4). However, it 
is important to note that for age 40-49 years, model (5.4) only captures predictions quite 
well for up to calendar year 2000 whereas model (5.5) captures predictions quite well for 
calendar years after the mid-1970s. Although it may appear that both models are 
supportive of the observed data, model (5.5) has a better predictive quality than model 
(5.4) for calendar years beyond 2000 for all age groups. Therefore model (5.5) seem 
more appropriate for making prediction of future forces of mortality for White American 
prostate cancer patients. Thus, model (5.5) will be adopted as the representative modeling 
structure for estimating mortality rates for White Americans. The analytical form of the 
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statistical model driven by the estimates of the weights of the attributable variables is 
given by, 
                           
              
             
             
                                                  
                
      
                              
    .  
Using the above model, an eleven year projection of the force of mortality      for age 
range   = 20 to 105 years at 5-yearly intervals, for calendar years   = 2010 to 2020 at 1-
yearly interval is given by Figure 5.6. From the graph, all the predicted forces of 
mortality progress smoothly with respect to both age and time with the highest rate of 
improvement at younger ages and the rate of improvement reduces at older ages. 
 
Figure 5.5: Estimated mortality rates versus crude mortality rates for White Americans 
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Figure 5.6: 11-year predicted mortality rates by age for White Americans 
5.4.2 Mortality of African Americans 
The mortality data for African Americans was modeled for individual calendar years 
            for individual ages   ranging from 42 to 87+ years. The force of 
mortality      at age  , in calendar year   was modeled using equation (5.1) with the 
transformed age    and transformed calendar year    defined by, 
   
      
    
  and     
      
  
, 
respectively. The transformation rescaled the age and calendar years onto the interval [-1, 
1]. To determine the optimum values of   and  , we fit the model for age effects with the 
multiplicative age independent trend adjustment term for increasing values of   and   and 
examine the improvement in the deviance and also checking for the significance of the 
parameter estimates. Table 5.5 represents the deviance profile with increasing values of   
and  . Each adjacent increase in row or column deviance is a relative measure of 
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goodness-of-fit which is an approximation to the chi-squared distribution with one degree 
of freedom. We have settled for     and     because beyond this point, the 
parameter estimates were not statistically significant at the 5% level. Based on this 
predetermined values of   and   the model is refined by introducing the age dependent 
trend adjustment terms in the sequence of increasing degree of the mixed product terms. 
The deviance profile for the inclusion of the mixed product terms is given in Table 5.6. 
Table 5.5: Deviance profile for various predictors of degree s and r for African 
Americans 
 
                        
    3567.6 3026.7 2945.9 2939.4 2925.2 2924.4 
    1160.1 618.95 536.88 530.62 516.21 515.44 
    1146.9 605.74 523.63 517.37 502.96 502.18 
    1145.6 604.49 522.36 516.11 501.70 500.92 
    1143.4 602.24 520.15 513.89 499.49 498.71 
    1141.5 600.31 518.17 511.92 497.51 496.73 
 
Table 5.6: Deviance profile for additional mixed product terms 
   
Difference 
 
Deviance d.f. Deviance d.f. 
        523.63 366 
  
    233.19 365 290.44 1 
    232.73 364 0.46 1 
    232.21 363 0.52 1 
    157.43 362 74.78 1 
    150.90 361 6.53 1 
    145.98 360 4.92 1 
    132.69 359 13.29 1 
    132.23 358 0.46 1 
    131.40 357 0.83 1 
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The deviance profile for the mixed effects suggest the possible inclusion of the product 
terms involving the parameters    ,    ,    ,     and    . However, monitoring the 
statistical significance of the parameter estimates with the inclusion of all possible 
product terms, we identified that the data was supportive of three different models. The 
analytical structure of the first identified model is given by, 
        [   ∑       
   ∑     
  ∑        
                 
        
 
   ], (5.6) 
with corresponding quasi-likelihood parameter estimates given in Table 5.7. The residual 
deviance associated with this model is approximately 144.74 with 363 degrees of 
freedom. The scale parameter         measures the degree of over dispersion present 
and is estimated by dividing the residual deviance by the associated degrees of freedom. 
The analytical structure of the second identified model is given by, 
        [   ∑       
   ∑     
         
            
        
 
   ], (5.7) 
with corresponding quasi-likelihood parameter estimates given in Table 5.8. The residual 
deviance associated with this second model is approximately 146.77 with 364 degrees of 
freedom. The scale parameter   is approximately 0.403. 
The analytical structure of the third identified model is given by, 
        [   ∑       
   ∑     
         
            
        
 
   ], (5.8) 
with corresponding quasi-likelihood parameter estimates given in Table 5.9. The residual 
deviance associated with this third model is approximately 159.65 with 364 degrees of 
freedom. The scale parameter   is approximately 0.439. 
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Table 5.7: Parameter estimates of model (5.6) for African Americans 
Parameter Estimate S.E. t-value 
   3.493426 0.016117 216.753*** 
   3.386463 0.033961 99.716*** 
   -1.079349 0.032748 -32.959*** 
   0.084311 0.016866 4.999*** 
   0.001824 0.017847 0.102 
   -0.344929 0.022017 -15.667*** 
   -0.280808 0.019886 -14.121*** 
    0.235257 0.020621 11.409*** 
    -0.067677 0.029977 -2.258* 
    0.184312 0.012422 14.837*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
Table 5.8: Parameter estimates of model (5.7) for African Americans 
Parameter Estimate S.E. t-value 
   3.5072633 0.0149730 234.239*** 
   3.3651063 0.0328025 102.587*** 
   -1.0792521 0.0329694 -32.735*** 
   0.0843392 0.0169797 4.967*** 
   0.0005636 0.0179871 0.031 
   -0.3888624 0.0104240 -37.305*** 
   -0.2842568 0.0199610 -14.241*** 
    0.2394138 0.0208134 11.503*** 
    0.1823829 0.0124985 14.592*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
A plot of the estimated mortality rates for the three identified models together with the 
crude mortality rates is given by Figure 5.7. The first and second models (models 5.6 & 
5.7) show similar predictive qualities for all age groups and calendar years. However, 
there is a small difference between the predictive qualities of models (5.6 & 5.7) versus 
model (5.8) for age 40-49 years. This difference is more evident at age 40-44 years 
because only model (5.8) was able to capture the crude mortality rates for this age group.  
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Table 5.9: Parameter estimates of model (5.8) for African Americans 
Parameter Estimate S.E. t-value 
   3.50865 0.01555 225.567*** 
   3.36043 0.03408 98.612*** 
   -1.07264 0.03429 -31.277*** 
   0.08208 0.01768 4.643*** 
   0.10998 0.02345 4.690*** 
   -0.38838 0.01088 -35.704*** 
   -0.28398 0.02083 -13.632*** 
    -0.03342 0.03968 -0.842 
    0.32661 0.02528 12.919*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
In view of this, model (5.8) seem more appropriate for making predictions of future 
forces of mortality for African American prostate cancer patients. Thus, model (5.8) will 
be adopted as the representative modeling structure for estimating mortality rates for 
African Americans. The analytical form of the statistical model driven by the estimates of 
the weights of the attributable variables is given by, 
                           
              
              
   
                                                               
     
                               
    . 
Using the above model, an eleven year projection of the force of mortality      for age 
range   = 20 to 105 years at 5-yearly intervals, for calendar years   = 2010 to 2020 at 1-
yearly interval is given by Figure 5.8. From the graph, all the predicted forces of 
mortality progress smoothly with respect to both age and time with the highest rate of 
improvement at the middle ages and the least improvement at older and some younger 
ages. 
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Figure 5.7: Estimated mortality rates versus crude mortality rates for African Americans 
 
Figure 5.8: 11-year predicted mortality rates by age for African Americans 
5.4.3 Comparison of White and African Americans 
A graphical display comparing the mortality rates between White and African Americans 
is given by Figure 5.9. 
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Figure 5.9: Comparison of mortality rates between White and African Americans 
The projected force of mortality progress smoothly for both race at all ages over time. 
This is an indication that the rate of improvement is quite similar for both races. 
Generally, the greatest improvement occurs at relatively younger ages and the least 
improvement occurs at older ages. It can be seen that, prostate cancer mortality rates are 
relatively higher in African Americans than White Americans. This is evident among 
individuals below the age of 70 years. 
5.5 Modeling and Analysis of Mortality Rate by Region 
Data from nineteen SEER registries were classified into four regions as follows: 
Northeast (Connecticut & New Jersey), Midwest (Metropolitan Detroit & Iowa), South 
(Metropolitan Atlanta, Kentucky, Louisiana & Greater Georgia), and West (San 
Francisco-Oakland, Hawaii, New Mexico, Seattle-Puget Sound, Utah, San Jose-
Monterey, Los Angeles, Alaska, Arizona & California-excluding San Francisco-Oakland, 
San Jose-Monterey, and Los Angeles). 
202020152010 202020152010
8
0
-8
8
0
-8
202020152010
8
0
-8
202020152010
8
0
-8
202020152010
20
Time (in years)
L
o
g
 M
o
rt
a
li
ty
 R
a
te
25 30 35 40
45 50 55 60 65
70 75 80 85 90
95 100 105
African Americans
White Americans
Variable
Comparison of Mortality Rates by Race Stratified by Age
 114 
 
 
Figure 5.10: Log crude mortality rate by region of classification 
A plot of the overall crude mortality rates on the log scale as a function of calendar year   
by region of classification is given by Figure 5.10. It can be seen that mortality rates were 
relatively higher in the South and Midwest regions than the West and Northeast regions. 
A decline in mortality rate in all four regions began in the early 1990s with some 
considerable variation in the rates over time. 
5.5.1 Mortality of Northeast Region  
Information for calendar years 1969-2009 and age groups 50-54, 55-59, 60-64, …, 85+ 
years were available for analysis. With the exception of age group 50-54 years, there was 
complete information for calendar years 1969 to 2009 with one year duration giving a 
total of 304 observations. A graphical display of the crude mortality rate on the log scale 
as a function of calendar year for each age group is given by Figure 5.11. 
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Figure 5.11: Log crude mortality rate for Northeast region 
The force of mortality      at age  , in calendar year   was modeled using equation (5.1) 
with the transformed age    and transformed calendar year    defined by, 
   
      
    
  and     
      
  
, 
respectively. The deviance profile for determining the optimum values of   and   is given 
in Table 5.10. 
Each adjacent increase in row or column deviance is a relative measure of goodness-of-fit 
approximated as chi-squared distribution with one degree of freedom. Scrutinizing the 
improvement in the deviance profile we settle for the optimum values     and    . 
Now, the model is refined by introducing the age dependent trend adjustment terms in 
order of increasing degree of the product terms. The deviance profile for inclusion of the 
product terms is given in Table 5.11.  
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Table 5.10: Deviance profile for various predictors of degree s and r for Northeast region 
 
                        
    1048.2 830.26 806.33 805.19 791.71 791.33 
    509.61 288.89 265.28 264.23 251.40 251.22 
    508.65 287.83 264.22 263.18 250.38 250.20 
    508.23 287.48 263.87 262.82 250.00 249.82 
    507.87 287.18 263.56 262.51 249.68 249.49 
    507.13 286.49 262.86 261.81 248.97 248.78 
 
Table 5.11: Deviance profile for additional mixed product terms 
   
Difference 
 
Deviance d.f. Deviance d.f. 
        265.28 298 
  
    204.98 297 60.30 1 
    183.91 296 21.07 1 
    183.82 295 0.09 1 
    159.24 294 24.58 1 
    153.98 293 5.26 1 
    153.28 292 0.70 1 
 
The resulting profile suggest possible inclusion of product terms involving the 
parameters,    ,    ,    , and    . However, product terms involving the parameters     
and     were the only contributing terms to the already predetermined model. Thus, the 
recommended model for estimating mortality rate in the northeast region is given by, 
        [   ∑       
   ∑     
         
            
         
 
   ], (5.9) 
with corresponding parameter estimates given in Table 5.12. The deviance residual for 
this model is approximately 183.91 with 296 degrees of freedom giving an estimated 
scale parameter of approximately 0.6213. 
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Table 5.12: Parameter estimates of model (5.9) for Northeast region 
Parameter Estimate S.E. t-value 
   3.64368 0.01495 243.660*** 
   2.11981 0.02644 80.160*** 
   -0.47861 0.01687 -28.373*** 
   -0.10910 0.02690 -4.056*** 
   -0.49986 0.03259 -15.340*** 
   -0.22336 0.03463 -6.450*** 
    0.24638 0.02384 10.336*** 
    0.25483 0.04410 5.778*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
A plot of the estimated mortality rates has been superimposed onto the crude mortality 
rates on the log scale as a function of calendar year for each age group to assess and 
validate the predictive quality of the recommended model (5.9). This is represented by 
Figure 5.12. Visually, it can be seen that estimates of the recommended model (5.9) 
captures the observed crude mortality rates for all age groups which is an indication of 
the quality of the model. The analytical form of the statistical model driven by estimates 
of the weights of the attributable variables is given by, 
                           
              
                       
                                          
                
     .  
Using the above model, an eleven year projection of the force of mortality      for age 
range x = 20 to 105 years at 5-yearly intervals, for calendar years t = 2010 to 2020 at 1-
yearly interval is given by Figure 5.13. All the predicted forces of mortality progress 
smoothly with respect to both age and time with the highest rate of improvement at 
younger ages and the rate decreases at older ages. 
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Figure 5.12: Estimated mortality rates versus crude mortality rates for Northeast region 
 
Figure 5.13: 11-year predicted mortality rates by age for Northeast region 
5.5.2 Mortality of Midwest Region  
Complete information for calendar years 1969 to 2009 with one year duration for age 
groups 60-64, 65-69, 70-74, …, 85+ years together with partial calendar year information 
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for age group 50-59 years gave a total of 280 observations for analysis. A plot of the 
crude mortality rate on the log scale as a function of calendar year for each age group is 
given by Figure 5.14. Notice that, age group 50-54 years had observation for only one 
time point. Therefore, this observation will not be included in the modeling of mortality 
rates for Midwest region. 
 
Figure 5.14: Log crude mortality rate for Midwest region 
The force of mortality      at age  , in calendar year   was modeled using equation (5.1) 
with the transformed age    and transformed calendar year    defined by, 
   
    
  
  and     
      
  
, 
respectively. The optimum values of   and   was determined by fitting a model for age 
effects with multiplicative age independent trend adjustment term and monitoring the 
improvement in the model deviance as values of r and s are increased. In addition, the 
significance of the parameter estimates was also checked. Table 5.13 represents the 
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deviance profile for determining the optimum values of s and r. Based on the observed 
changes in the model deviance and the significance of the parameter estimates, the 
optimum values of r and s are 3 and 2, respectively. Now, this predetermined model is 
refined by introducing the interaction terms in a sequence of increasing degree. The 
model deviance for including the interaction terms is given in Table 5.14. 
Table 5.13: Deviance profile for various predictors of degree s and r for Midwest region 
 
                        
    1003.1 866.01 796.41 794.88 783.05 782.62 
    526.69 388.14 321.59 320.27 309.47 309.19 
    526.68 388.12 321.59 320.26 309.47 309.19 
    525.77 387.25 320.69 319.36 308.54 308.26 
    521.18 382.75 316.51 315.14 304.35 304.09 
    520.54 382.10 315.63 314.27 303.45 303.17 
 
Table 5.14: Deviance profile for additional mixed product terms 
   
Difference 
 
Deviance d.f. Deviance d.f. 
        321.59  274 
  
    257.43 273 64.16 1 
    233.06 272 24.37 1 
    232.14 271 0.92 1 
    212.33 270 19.81 1 
    195.83 269 16.50 1 
    195.73 268 0.10 1 
 
Changes in the model deviance suggest the inclusion of the terms involving the 
parameters    ,    ,    , and    . Including these terms while checking for the 
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significance of the parameter estimates, we identified an appropriate model for estimating 
the mortality rate for Midwest region. The analytical structure of the model is given by, 
        [   ∑       
   ∑     
  ∑        
         
 
   
 
   ],   (5.10) 
with corresponding parameter estimates given in Table 5.15. The residual deviance for 
this model is approximately 233.06 on 272 degrees of freedom with an approximate scale 
parameter of 0.8568. All the parameter estimates are statistically significant at the 0.1% 
level except for the term involving the parameter   . In order to assess and validate the 
quality of model (5.10), a plot of the estimated mortality rate on the log scale was 
superimposed onto the crude mortality rate as a function of calendar year for each age 
group. This is represented by Figure 5.15. 
Table 5.15: Parameter estimates of model (5.10) for Midwest region 
Parameter Estimate S.E. t-value 
   3.71126 0.01791 207.256*** 
   2.06662 0.03258 63.426*** 
   -0.47870 0.02079 -23.028*** 
   -0.05873 0.03078 -1.908 
   -0.43748 0.03726 -11.742*** 
   -0.35626 0.03937 -9.049*** 
    0.25243 0.02744 9.200*** 
    0.26793 0.05067 5.288*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
By way of assessment, it can be seen that the estimated mortality rates by model (5.10) 
captures the crude mortality rates quite well. Thus, model (5.10) seems appropriate for 
estimating mortality rates for Midwest region. The analytical form of the statistical model 
driven by the estimates of the weights of the attributable variables is given by, 
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Figure 5.15: Estimated mortality rates versus crude mortality rates for Midwest region 
 
Figure 5.16: 11-year predicted mortality rates by age for Midwest region 
6
4
2
201019951980
201019951980
6
4
2
201019951980
6
4
2
55-59
Time (in years)
L
o
g
 M
o
rt
a
li
ty
 R
a
te
60-64 65-69
70-74 75-79 80-84
85+
Observed
Estimated
Variable
Estimated and Crude Mortality Rate for Midwest Region
202020182016201420122010
5
0
-5
-10
-15
Time (in years)
L
o
g
 M
o
rt
a
li
ty
 R
a
te
65
70
75
80
85
90
95
100
105
20
25
30
35
40
45
50
55
60
Age
Projected Force of Mortality for Midwest Region
 123 
 
Using this model, the projected force of mortality      for age range x = 20 to 105 years 
at 5-yearly intervals, for calendar years t = 2010 to 2020 at 1-yearly interval is given by 
Figure 5.16. The predicted forces of mortality progress smoothly with both age and time 
with the least improvement occurring at older ages.  
5.5.3 Mortality of South Region  
A total of 296 observations representing complete information for calendar years 1969 to 
2009 with one year duration for age groups 55-59, 60-64, …, 85+ years and partial 
calendar year information for age group 50-54 years was available for analysis. A display 
of the crude mortality rate on the log scale as a function of calendar year for each age 
group is given by Figure 5.17. 
 
Figure 5.17: Log crude mortality rate for South region 
In this region, the force of mortality      at age  , in calendar year   was modeled using 
equation (5.1) with the transformed age    and transformed calendar year    defined by, 
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  and     
      
  
, 
respectively. The model was fitted for age effects with multiplicative age independent 
trend adjustment term for calendar year effects to determine the optimum values of r and 
s by monitoring the improvement in the model deviance as values of r and s are increased 
and also checking for the significance of the parameter estimates. The corresponding 
deviance profile is given in Table 5.16.  
The observed changes in the model deviance and the significance of the parameter 
estimates, reveal the optimum values as     and    . Based on this predetermined 
optimum value, the model is refined by introducing the interaction terms in order of 
increasing degree. The deviance profile for inclusion of the interaction terms are given in 
Table 5.17. A review of the difference in the deviance profile suggest the possible 
inclusion of terms involving the parameters    ,    ,    ,   ,    , and    . However, it 
was observed that models with     were only useful for predictions of future forces of 
mortality provided the predictions are made within the range of ages over which the 
model has been fitted. By way of illustration, we have presented one scenario by Figure 
5.18. Here, the model provides reasonable predictions only for age range 45 to 85 years.  
Table 5.16: Deviance profile for various predictors of degree s and r for South region 
 
                        
    1131.3 916.54 858.48 851.37 840.14 839.99 
    627.11 411.86 352.58 344.94 332.41 332.33 
    626.68 411.44 352.19 344.58 332.07 332.00 
    625.40 410.20 351.03 343.44 331.03 330.95 
    623.52 408.36 349.29 341.75 329.43 329.35 
    623.08 407.93 348.89 341.36 329.07 328.99 
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Table 5.17: Deviance profile for additional mixed product terms 
   
Difference 
 
Deviance d.f. Deviance d.f. 
        332.41 288 
  
    188.90 287 143.51 1 
    180.50 286 8.40 1 
    180.21 285 0.29 1 
    178.29 284 1.92 1 
    175.58 283 2.71 1 
    148.52 282 27.06 1 
    137.01 281 11.51 1 
    136.96 280 0.05 1 
    136.83 279 0.13 1 
    136.83 278 0.00 1 
 
 
Figure 5.18: Illustration of predicted force of mortality for     for South region 
Although models with     provides a better fit within the range of ages for which the 
data was fitted there was a trade-off between goodness-of-fit and both goodness-of-fit 
20102000199019801970
5
0
-5
-10
Time (in years)
L
o
g
 M
o
rt
a
li
ty
 R
a
te
65
70
75
80
85
90
95
100
105
20
25
30
35
40
45
50
55
60
Age
Predicted Force of Mortality
 126 
 
and predictive quality. In view of this, the analytical model described by (5.11) seems 
appropriate for estimating and making predictions of future forces of mortality for the 
South region. 
        [   ∑       
   ∑     
  ∑        
             
        
 
   
 
   ]. (5.11) 
The quasi-likelihood parameter estimates for model (5.11) are given in Table 5.18. The 
residual deviance corresponding to this model is approximately 173.1 on 287 degrees of 
freedom with estimated scale parameter of 0.6031. All the parameter estimates are 
statistically significant at the 5% level. 
Table 5.18: Parameter estimates of model (5.11) for South region 
Parameter Estimate S.E. t-value 
   3.76010 0.01391 270.240*** 
   2.02646 0.02483 81.627*** 
   -0.44338 0.01596 -27.784*** 
   0.06305 0.02743 2.298* 
   -0.41233 0.02955 -13.952*** 
   -0.33059 0.03276 -10.090*** 
    0.11854 0.03910 3.032** 
    0.13686 0.04056 3.374*** 
    0.19428 0.02865 6.781*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
By way of assessing and validating the predictive quality of the model, the estimated 
mortality rates by model (5.11) together with the crude mortality rates are plotted against 
calendar year t on the log scale as shown by Figure 5.19. It can be seen that the observed 
mortality rates are well captured by the estimated rates from model (5.11) except for 
maybe age 50-54 years. The analytical form of the statistical model driven by the 
estimates of the weights of the attributable variables is given by, 
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Figure 5.19: Estimated mortality rates versus crude mortality rates for South region 
 
Figure 5.20: 11-year predicted mortality rates by age for South region 
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Using this model, the projected force of mortality      for age range x = 20 to 105 years 
at 5-yearly intervals for calendar years t = 2010 to 2020 at 1-yearly interval is given by 
Figure 5.20. By visual inspection, all the predicted forces of mortality progress smoothly 
with both age and time with the least improvement at older ages and greatest 
improvement at younger ages. 
5.5.4 Mortality of West Region  
Complete information for calendar years 1969 to 2009 with one year duration for age 
groups 50-59, 60-64, 65-69, …, 85+ years together with partial calendar year information 
for age group 50-54 years gave a total of 318 observations for analysis. A plot of the 
crude mortality rate on the log scale as a function of calendar year for each age group is 
given by Figure 5.21. 
 
Figure 5.21: Log crude mortality rate for West region 
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The force of mortality      at age  , in calendar year   was modeled using equation (5.1) 
with the transformed age    and transformed calendar year    defined by, 
   
      
    
  and     
      
  
, 
respectively. Models for age effects with multiplicative age independent calendar year 
effects were fitted to the observed data to determine the optimum values of r and s by 
monitoring the improvement in the model deviance as values of r and s are increased and 
also checking for the significance of the parameter estimates. The deviance profile 
corresponding to this process is given in Table 5.19.  
Table 5.19: Deviance profile for various predictors of degree s and r for West region 
 
                        
    875.30 725.77 709.99 696.20 690.24 689.78 
    389.35 240.05 224.17 210.56 204.48 203.97 
    386.78 237.49 221.62 208.02 201.92 201.41 
    385.97 236.69 220.81 207.22 201.12 200.61 
    385.97 236.69 220.81 207.21 201.12 200.60 
    385.90 236.62 220.74 207.15 201.05 200.54 
 
Changes in adjacent row and column deviance values together with the significance of 
the parameter estimates suggest an optimum value of     and    . Based on this 
predetermined optimum value, the model is refined by introducing the product terms in 
order of increasing degree. The resulting deviance profile for including the product terms 
is given in Table 5.20.  
A review of the deviance profile suggest the possible inclusion of terms involving the 
parameters    ,    ,    ,    ,    ,    ,    , and    . However, as discussed in section 
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(5.5.3), models with     were only useful for predicting the force of mortality within 
the range of ages over which the model was fitted. Similar situations were encountered in 
the modeling of mortality rates in this region. The appropriate model for estimating and 
predicting mortality rates for the West region is given by, 
        [   ∑       
   ∑     
  ∑        
             
        
 
   
 
   ], (5.12) 
with quasi-likelihood parameter estimates given in Table 5.21. The corresponding 
residual deviance is approximately 92.523 on 307 degrees of freedom with estimated 
scale parameter of 0.3014. All the parameter estimates are statistically significant at the 
5% level except the term involving the parameter   . 
Table 5.20: Deviance profile for additional mixed product terms 
   
Difference 
 
Deviance d.f. Deviance d.f. 
        201.92 309 
  
    116.93 308 84.99 1 
    94.169 307 22.761 1 
    91.537 306 2.632 1 
    87.425 305 4.112 1 
    87.061 304 0.364 1 
    68.254 303 18.807 1 
    61.567 302 6.687 1 
    60.917 301 0.65 1 
    59.148 300 1.769 1 
    58.699 299 0.449 1 
    56.920 298 1.779 1 
    56.806 297 0.114 1 
    56.628 296 0.178 1 
    56.429 295 0.199 1 
    56.307 294 0.122 1 
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Table 5.21: Parameter estimates of model (5.12) for West region 
Parameter Estimate S.E. t-value 
   3.60701 0.01067 338.157*** 
   2.15571 0.01932 111.593*** 
   -0.46482 0.01913 -24.293*** 
   0.03124 0.01276 2.449* 
   -0.11121 0.02914 -3.817*** 
   -0.43217 0.02252 -19.188*** 
   -0.08296 0.04304 -1.928 
    0.18693 0.04426 4.223*** 
    0.24733 0.03011 8.214*** 
    -0.15995 0.05771 -2.772** 
    0.16262 0.02048 7.941*** 
('***' p-value < 0.001, '**' p-value < 0.01, '*' p-value < 0.05) 
Figure 5.22 shows the plot of the estimated mortality rates by model (5.12) together with 
the crude mortality rates on the log scale against calendar year t as a way of assessing and 
validating the predictive quality of the proposed model. It can be seen that the observed 
mortality rates are well captured by the estimated rates for all age groups. Thus, the 
analytical form of the statistical model driven by the estimates of the weights of the 
attributable variables is given by, 
                           
              
              
   
                                                               
     
                               
                 
                 
    .  
Using the above model, the projected force of mortality      for age range x = 20 to 105 
years at 5-yearly intervals for calendar years t = 2010 to 2020 at 1-yearly interval is given 
by Figure 5.23. All the predicted forces of mortality progress smoothly with respect to 
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both age and time with the least improvement at older ages and some younger ages and 
the greatest improvement at the middle ages. 
 
Figure 5.22: Estimated mortality rates versus crude mortality rates for West region 
 
Figure 5.23: 11-year predicted mortality rates by age for West region 
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5.5.5 Regional Comparison 
A graphical display comparing the mortality rates of the four geographic regions is given 
by Figure 5.24.  
 
Figure 5.24: Comparison of mortality rates by region stratified by age 
The forces of mortality progress smoothly over time for all age groups in the four 
geographic regions. However, the regional rate of mortality improvement varies among 
different age groups. Generally, the greatest improvement is expected at relatively 
younger ages. However, it can be seen that the improvement among younger ages is only 
evident in the Northeast and Midwest regions. Also, the rate of mortality is relatively 
higher in the South and West regions for individuals’ age 50 years and below. For age 
group 55 to 100 years, the rate of mortality appears to be similar in all the regions. 
Beyond age 100 years, the pattern of mortality rates appears to be increasing slightly in 
the South and West regions. 
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5.6 Conclusion 
This present study has shown that Renshaw et al. (1996) proposed modeling structure can 
be used to predict future forces of mortality provided the trend adjustment term has an 
order not more than three and the coefficients are themselves linear. One major benefit of 
the developed models is to estimate or predict forces of mortality as a function of age and 
calendar year. 
Achievement in medical science and public health services have resulted in an almost 
continuous reduction in the death rates of prostate cancer since the early 1990s and future 
projections continue to show a decline mostly at the younger ages with the rate of 
improvement relatively higher in White Americans than African Americans and also, 
relatively higher in Northeast and Midwest regions than South and West regions. 
This reduction can be interpreted as a measure of progress against prostate cancer as it 
reflects improvement in prevention, early detection, and treatment. Furthermore, a 
decline in mortality rates is a favorable feature in the growth of life insurance business 
and not annuity. Therefore the use of natural hedging can be used to stabilize the 
aggregate outflow of insurers. 
Generally, prostate cancer mortality rates are relatively higher in Africa Americans than 
White Americans. However, results of this study have revealed that this is evident at age 
70 years and below. Also, for regional mortality, the death rates are relatively higher in 
the South and West regions than the Northeast and Midwest regions mostly for 
individuals’ age 50 years and below.  
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These are very useful results for policy makers in government as well as insurance 
business. 
5.7 Contributions 
In this chapter we have developed statistical models for addressing some important issues 
concerning prostate cancer mortality. 
 We have developed statistical models for estimating mortality rates for White and 
African Americans as well as regional mortality. 
 The developed models have predicted a decline in mortality rates. However, these 
declines are more evident among the younger age group than the older age group. 
 Racial comparison has shown that prostate cancer mortality rate is relatively 
higher among African American men than White American men.  
 Also, regional comparison has shown that the mortality rate is relatively higher in 
the South and West regions than the Northeast and Midwest regions. 
 The observed decline in mortality rates serves as a measure of improvement 
against prostate cancer disease. 
 These findings are very useful for policy makers as well as insurance business. 
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Chapter 6: Future Research 
 
Some factors like age, race, nationality, family history, genes, diet, obesity, smoking, 
inflammation of the prostate, sexually transmitted infections, and vasectomy have been 
proposed as possible risk factors of prostate cancer. Using prostate tumor size as a 
response variable, our future goal is to develop a statistical model for estimating the 
prostate tumor size as a function of the proposed attributable variables with interactions. 
Based on the developed model, we will proceed to perform surface response analysis to 
determine the optimal estimates necessary to minimize the response variable, tumor size. 
The power law process or non-homogenous Poisson process is widely used in reliability 
analysis. The methodology incorporates an intensity function which measures the level of 
reliability in a given process. As a future work, this methodology will be applied to 
evaluate the effectiveness of the treatment options considered in chapter 4 of this study 
with possible extensions to include other treatment options based on the availability of 
data. The results of this proposed future study will be compared with the results of the 
study in chapter 4. 
One major problem concerning patients and more especially doctors is a way to 
determine which cancers are likely to stay within the gland and which are more likely to 
grow and spread. These problems require a better understanding of the biological process 
involved in the growth and spread of the cancers and possibly use differential equation 
and/or Markovian analysis if applicable. 
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